Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Multiple Sclerosis

  Free Subscription


Articles published in Mult Scler

Retrieve available abstracts of 483 articles:
HTML format
Text format



Single Articles


    April 2017
  1. COETZEE T, Thompson A
    When are we going to take modifiable risk factors more seriously in multiple sclerosis?
    Mult Scler. 2017;23:494-495.
    PubMed     Text format    


    March 2017
  2. BOGIE JF, Boelen E, Louagie E, Delputte P, et al
    CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517698759. doi: 10.1177/1352458517698759.
    PubMed     Text format     Abstract available


  3. PITAROKOILI K, Hellwig K, Lukas C, Gold R, et al
    Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis.
    Mult Scler. 2017;23:483-486.
    PubMed     Text format     Abstract available


  4. ARRAMBIDE G
    Commentary on "Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis".
    Mult Scler. 2017;23:486-487.
    PubMed     Text format    


  5. MARRIE RA
    What is the risk of suicide in multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517699992. doi: 10.1177/1352458517699992.
    PubMed     Text format    


  6. KALSON-RAY S, Edan G, Leray E
    An excessive risk of suicide may no longer be a reality for multiple sclerosis patients.
    Mult Scler. 2017 Mar 1:1352458517699873. doi: 10.1177/1352458517699873.
    PubMed     Text format     Abstract available


  7. LEURS CE, Podlesniy P, Trullas R, Balk L, et al
    Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.
    Mult Scler. 2017 Mar 1:1352458517699874. doi: 10.1177/1352458517699874.
    PubMed     Text format     Abstract available


  8. ROCCA MA, Valsasina P, Leavitt VM, Rodegher M, et al
    Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment.
    Mult Scler. 2017 Mar 1:1352458517699875. doi: 10.1177/1352458517699875.
    PubMed     Text format     Abstract available


  9. RIO J, Rovira A, Tintore M, Otero-Romero S, et al
    Disability progression markers over 6-12 years in interferon-beta-treated multiple sclerosis patients.
    Mult Scler. 2017 Mar 1:1352458517698052. doi: 10.1177/1352458517698052.
    PubMed     Text format     Abstract available


  10. CORTESE M, Riise T, Bjornevik K, Myhr KM, et al
    Body size and physical exercise, and the risk of multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517699289. doi: 10.1177/1352458517699289.
    PubMed     Text format     Abstract available


  11. RANGANATHAN U, Kaunzner U, Foster S, Vartanian T, et al
    Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517699876. doi: 10.1177/1352458517699876.
    PubMed     Text format     Abstract available


  12. FEINSTEIN A, Pavisian B
    Multiple sclerosis and suicide.
    Mult Scler. 2017 Mar 1:1352458517702553. doi: 10.1177/1352458517702553.
    PubMed     Text format     Abstract available


  13. CHARVET LE, Shaw M, Frontario A, Langdon D, et al
    Cognitive impairment in pediatric-onset multiple sclerosis is detected by the Brief International Cognitive Assessment for Multiple Sclerosis and computerized cognitive testing.
    Mult Scler. 2017 Mar 1:1352458517701588. doi: 10.1177/1352458517701588.
    PubMed     Text format     Abstract available


    February 2017
  14. HEMPEL S, Graham GD, Fu N, Estrada E, et al
    A systematic review of the effects of modifiable risk factor interventions on the progression of multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690271. doi: 10.1177/1352458517690271.
    PubMed     Text format     Abstract available


  15. HEMPEL S, Graham GD, Fu N, Estrada E, et al
    A systematic review of modifiable risk factors in the progression of multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690270. doi: 10.1177/1352458517690270.
    PubMed     Text format     Abstract available


  16. PRAVATA E, Rocca MA, Valsasina P, Riccitelli GC, et al
    Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692886. doi: 10.1177/1352458517692886.
    PubMed     Text format     Abstract available


  17. CARPENTER AF, Goodwin SJ, Bornstein PF, Larson AJ, et al
    Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
    Mult Scler. 2017;23:297-299.
    PubMed     Text format     Abstract available


  18. CAMERON MH, McMillan G
    Methylphenidate is likely less effective than placebo for improving imbalance, walking, and fatigue in people with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692421. doi: 10.1177/1352458517692421.
    PubMed     Text format    


  19. SONNENBERG A, Ajdacic-Gross V
    Similar birth-cohort patterns in Crohn's disease and multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517691620. doi: 10.1177/1352458517691620.
    PubMed     Text format     Abstract available


  20. BALCER LJ, Raynowska J, Nolan R, Galetta SL, et al
    Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690822. doi: 10.1177/1352458517690822.
    PubMed     Text format     Abstract available


  21. MOTL RW, Cohen JA, Benedict R, Phillips G, et al
    Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690823. doi: 10.1177/1352458517690823.
    PubMed     Text format     Abstract available


  22. BENEDICT RH, DeLuca J, Phillips G, LaRocca N, et al
    Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690821. doi: 10.1177/1352458517690821.
    PubMed     Text format     Abstract available


  23. FEYS P, Lamers I, Francis G, Benedict R, et al
    The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690824. doi: 10.1177/1352458517690824.
    PubMed     Text format     Abstract available


  24. HULST HE, Thompson AJ, Geurts JJ
    The measure tells the tale: Clinical outcome measures in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690825. doi: 10.1177/1352458517690825.
    PubMed     Text format    


  25. SHOR N, Amador MD, Dormont D, Lubetzki C, et al
    Involvement of peripheral III nerve in multiple sclerosis patient: Report of a new case and discussion of the underlying mechanism.
    Mult Scler. 2017 Feb 1:1352458516687401. doi: 10.1177/1352458516687401.
    PubMed     Text format     Abstract available


  26. ROVIRA A
    Peripheral nervous system involvement in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517693469. doi: 10.1177/1352458517693469.
    PubMed     Text format    


  27. CORIC D, Balk LJ, Verrijp M, Eijlers A, et al
    Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers.
    Mult Scler. 2017 Feb 1:1352458517694090. doi: 10.1177/1352458517694090.
    PubMed     Text format     Abstract available


  28. GIACOMINI E, Rizzo F, Etna MP, Cruciani M, et al
    Thymosin-alpha1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2017 Feb 1:1352458517695892. doi: 10.1177/1352458517695892.
    PubMed     Text format     Abstract available


  29. GALAZKA G, Mycko MP, Selmaj I, Raine CS, et al
    Multiple sclerosis: Serum-derived exosomes express myelin proteins.
    Mult Scler. 2017 Feb 1:1352458517696597. doi: 10.1177/1352458517696597.
    PubMed     Text format     Abstract available


  30. MAILLEUX J, Vanmierlo T, Bogie JF, Wouters E, et al
    Active liver X receptor signaling in phagocytes in multiple sclerosis lesions.
    Mult Scler. 2017 Feb 1:1352458517696595. doi: 10.1177/1352458517696595.
    PubMed     Text format     Abstract available


  31. ROY S, Drake AS, Eizaguirre MB, Zivadinov R, et al
    Trait neuroticism, extraversion, and conscientiousness in multiple sclerosis: Link to cognitive impairment?
    Mult Scler. 2017 Feb 1:1352458517695467. doi: 10.1177/1352458517695467.
    PubMed     Text format     Abstract available


  32. SCHWARTZ CE, Grover SA, Powell VE, Noguera A, et al
    Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517695469. doi: 10.1177/1352458517695469.
    PubMed     Text format     Abstract available


  33. CACAO G, Santos E, Martins Silva A
    Concurrent autoimmune hepatitis in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692885. doi: 10.1177/1352458517692885.
    PubMed     Text format     Abstract available


  34. GOLAN D, Doniger GM, Wissemann K, Zarif M, et al
    The impact of subjective cognitive fatigue and depression on cognitive function in patients with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517695470. doi: 10.1177/1352458517695470.
    PubMed     Text format     Abstract available


  35. ZECCA C, Merlini A, Disanto G, Rodegher M, et al
    Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.
    Mult Scler. 2017 Feb 1:1352458517694089. doi: 10.1177/1352458517694089.
    PubMed     Text format     Abstract available


  36. KOBELT G, Thompson A, Berg J, Gannedahl M, et al
    New insights into the burden and costs of multiple sclerosis in Europe.
    Mult Scler. 2017 Feb 1:1352458517694432. doi: 10.1177/1352458517694432.
    PubMed     Text format     Abstract available


  37. WESNES K, Myhr KM, Riise T, Cortese M, et al
    Physical activity is associated with a decreased multiple sclerosis risk: The EnvIMS study.
    Mult Scler. 2017 Feb 1:1352458517694088. doi: 10.1177/1352458517694088.
    PubMed     Text format     Abstract available


  38. PATEL VP, Walker LA, Feinstein A
    Revisiting cognitive reserve and cognition in multiple sclerosis: A closer look at depression.
    Mult Scler. 2017 Feb 1:1352458517692887. doi: 10.1177/1352458517692887.
    PubMed     Text format     Abstract available


  39. CLERICO M, De Mercanti S, Artusi CA, Durelli L, et al
    Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.
    Mult Scler. 2017 Feb 1:1352458516688350. doi: 10.1177/1352458516688350.
    PubMed     Text format     Abstract available


  40. SHEIKH-TAHA M, Corman LC
    Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517694431. doi: 10.1177/1352458517694431.
    PubMed     Text format     Abstract available


    January 2017
  41. GONZALEZ TORRE JA, Cruz-Gomez AJ, Belenguer A, Sanchis-Segura C, et al
    Hippocampal dysfunction is associated with memory impairment in multiple sclerosis: A volumetric and functional connectivity study.
    Mult Scler. 2017 Jan 1:1352458516688349. doi: 10.1177/1352458516688349.
    PubMed     Text format     Abstract available


  42. MUNOZ MA, Kulick CG, Kortepeter CM, Levin RL, et al
    Liver injury associated with dimethyl fumarate in multiple sclerosis patients.
    Mult Scler. 2017 Jan 1:1352458516688351. doi: 10.1177/1352458516688351.
    PubMed     Text format     Abstract available


  43. MOTL RW, Mowry EM, Ehde DM, LaRocca NG, et al
    Wellness and multiple sclerosis: The National MS Society establishes a Wellness Research Working Group and research priorities.
    Mult Scler. 2017 Jan 1:1352458516687404. doi: 10.1177/1352458516687404.
    PubMed     Text format     Abstract available


  44. SUN H
    Temperature dependence of multiple sclerosis mortality rates in the United States.
    Mult Scler. 2017 Jan 1:1352458516688954. doi: 10.1177/1352458516688954.
    PubMed     Text format     Abstract available


  45. LEAVITT VM, Buyukturkoglu K, Inglese M, Sumowski JF, et al
    Protective personality traits: High openness and low neuroticism linked to better memory in multiple sclerosis.
    Mult Scler. 2017 Jan 1:1352458516685417. doi: 10.1177/1352458516685417.
    PubMed     Text format     Abstract available


  46. SONG J, Karrenbauer V, Manouchehrinia A, Almqvist C, et al
    Similar familial risk in multiple sclerosis subgroups.
    Mult Scler. 2017 Jan 1:1352458516684214. doi: 10.1177/1352458516684214.
    PubMed     Text format     Abstract available


  47. DE STEFANO N, Giorgio A, Battaglini M, De Leucio A, et al
    Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
    Mult Scler. 2017 Jan 1:1352458517690269. doi: 10.1177/1352458517690269.
    PubMed     Text format     Abstract available


  48. MA AY, Vitorino RC, Hojjat SP, Mulholland AD, et al
    The relationship between white matter fiber damage and gray matter perfusion in large-scale functionally defined networks in multiple sclerosis.
    Mult Scler. 2017 Jan 1:1352458517691149. doi: 10.1177/1352458517691149.
    PubMed     Text format     Abstract available


  49. BJORNEVIK K, Chitnis T, Ascherio A, Munger KL, et al
    Polyunsaturated fatty acids and the risk of multiple sclerosis.
    Mult Scler. 2017 Jan 1:1352458517691150. doi: 10.1177/1352458517691150.
    PubMed     Text format     Abstract available


  50. GOPAL S, Mikulskis A, Gold R, Fox RJ, et al
    Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.
    Mult Scler. 2017 Jan 1:1352458517690617. doi: 10.1177/1352458517690617.
    PubMed     Text format     Abstract available


  51. MANOUCHEHRINIA A, Westerlind H, Kingwell E, Zhu F, et al
    Age Related Multiple Sclerosis Severity Score: Disability ranked by age.
    Mult Scler. 2017 Jan 1:1352458517690618. doi: 10.1177/1352458517690618.
    PubMed     Text format     Abstract available


    December 2016
  52. MANOUCHEHRINIA A, Beiki O, Hillert J
    Clinical course of multiple sclerosis: A nationwide cohort study.
    Mult Scler. 2016 Dec 12. pii: 1352458516681197.
    PubMed     Text format     Abstract available


  53. BUDHRAM A, Parvathy S, Kremenchutzky M, Silverman M, et al
    Breaking down the gut microbiome composition in multiple sclerosis.
    Mult Scler. 2016 Dec 12. pii: 1352458516682105.
    PubMed     Text format     Abstract available


  54. KAPPOS L, Havrdova E, Giovannoni G, Khatri BO, et al
    No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
    Mult Scler. 2016 Dec 1:1352458516683266. doi: 10.1177/1352458516683266.
    PubMed     Text format     Abstract available


  55. CRISTOFANILLI M, Gratch D, Pagano B, McDermott K, et al
    Transglutaminase-6 is an autoantigen in progressive multiple sclerosis and is upregulated in reactive astrocytes.
    Mult Scler. 2016 Dec 1:1352458516684022. doi: 10.1177/1352458516684022.
    PubMed     Text format     Abstract available


  56. WIJNANDS JM, Kingwell E, Zhu F, Zhao Y, et al
    Infection-related health care utilization among people with and without multiple sclerosis.
    Mult Scler. 2016 Dec 1:1352458516681198. doi: 10.1177/1352458516681198.
    PubMed     Text format     Abstract available


  57. IKRAM MA, Vernooij MW, Roshchupkin GV, Hofman A, et al
    Genetic susceptibility to multiple sclerosis: Brain structure and cognitive function in the general population.
    Mult Scler. 2016 Dec 1:1352458516682104. doi: 10.1177/1352458516682104.
    PubMed     Text format     Abstract available


  58. BATISTA S, d'Almeida OC, Afonso A, Freitas S, et al
    Impairment of social cognition in multiple sclerosis: Amygdala atrophy is the main predictor.
    Mult Scler. 2016 Dec 1:1352458516680750. doi: 10.1177/1352458516680750.
    PubMed     Text format     Abstract available


  59. GHEZZI A
    Randomized clinical trials (RCTs) in pediatric multiple sclerosis: Are they really necessary?
    Mult Scler. 2016 Dec 1:1352458516684025. doi: 10.1177/1352458516684025.
    PubMed     Text format    


    November 2016
  60. GOLDMAN MD, Ward MD, Motl RW, Jones DE, et al
    Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale.
    Mult Scler. 2016 Nov 30. pii: 1352458516680749.
    PubMed     Text format     Abstract available


  61. HARRISON AM, das Nair R, Moss-Morris R
    Operationalising cognitive fatigability in multiple sclerosis: A Gordian knot that can be cut?
    Mult Scler. 2016 Nov 30. pii: 1352458516681862.
    PubMed     Text format     Abstract available


  62. SEPULVEDA M, Fernandez-Diez B, Martinez-Lapiscina EH, Llufriu S, et al
    Impairment of decision-making in multiple sclerosis: A neuroeconomic approach.
    Mult Scler. 2016 Nov 30. pii: 1352458516682103.
    PubMed     Text format     Abstract available


  63. DEVORAK J, Mokry LE, Morris JA, Forgetta V, et al
    Large differences in adiponectin levels have no clear effect on multiple sclerosis risk: A Mendelian randomization study.
    Mult Scler. 2016 Nov 30. pii: 1352458516681196.
    PubMed     Text format     Abstract available


  64. DATTA G, Violante IR, Scott G, Zimmerman K, et al
    Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis.
    Mult Scler. 2016 Nov 30. pii: 1352458516681504.
    PubMed     Text format     Abstract available


  65. VOORTMAN MM, Stojakovic T, Pirpamer L, Jehna M, et al
    Prognostic value of free light chains lambda and kappa in early multiple sclerosis.
    Mult Scler. 2016 Nov 29. pii: 1352458516681503.
    PubMed     Text format     Abstract available


  66. VENTURA RE, Antezana AO, Bacon T, Kister I, et al
    Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans.
    Mult Scler. 2016 Nov 29. pii: 1352458516679894.
    PubMed     Text format     Abstract available


  67. ROY S, Frndak S, Drake AS, Irwin L, et al
    Differential effects of aging on motor and cognitive functioning in multiple sclerosis.
    Mult Scler. 2016 Nov 24. pii: 1352458516679036.
    PubMed     Text format     Abstract available


  68. VAN DIJK PA, Kirk-Brown AK, Taylor B, van der Mei I, et al
    Closing the gap: Longitudinal changes in employment for Australians with multiple sclerosis.
    Mult Scler. 2016 Nov 24. pii: 1352458516678934.
    PubMed     Text format     Abstract available


  69. ARROYO GONZALEZ R, Kita M, Crayton H, Havrdova E, et al
    Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
    Mult Scler. 2016 Nov 24. pii: 1352458516677589.
    PubMed     Text format     Abstract available


  70. ABDOLLAHPOUR I, Nedjat S, Sahraian MA, Mansournia MA, et al
    Waterpipe smoking associated with multiple sclerosis: A population-based incident case-control study.
    Mult Scler. 2016 Nov 10. pii: 1352458516677867.
    PubMed     Text format     Abstract available


  71. CARLING A, Forsberg A, Gunnarsson M, Nilsagard Y, et al
    CoDuSe group exercise programme improves balance and reduces falls in people with multiple sclerosis: A multi-centre, randomized, controlled pilot study.
    Mult Scler. 2016 Nov 10. pii: 1352458516677591.
    PubMed     Text format     Abstract available


  72. SACCA F, Costabile T, Carotenuto A, Lanzillo R, et al
    The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests.
    Mult Scler. 2016 Nov 3. pii: 1352458516677592.
    PubMed     Text format     Abstract available


  73. MIKOLAJCZAK J, Zimmermann H, Kheirkhah A, Kadas EM, et al
    Patients with multiple sclerosis demonstrate reduced subbasal corneal nerve fibre density.
    Mult Scler. 2016 Nov 3. pii: 1352458516677590.
    PubMed     Text format     Abstract available


  74. CHATAWAY J
    Biotin in progressive multiple sclerosis: A new lead?
    Mult Scler. 2016;22:1640-1641.
    PubMed     Text format    


  75. GABILONDO I, Rilo O, Ojeda N, Pena J, et al
    The influence of posterior visual pathway damage on visual information processing speed in multiple sclerosis.
    Mult Scler. 2016 Nov 1:1352458516676642. doi: 10.1177/1352458516676642.
    PubMed     Text format     Abstract available


  76. CARUANA P, Lemmert K, Ribbons K, Lea R, et al
    Natural killer cell subpopulations are associated with MRI activity in a relapsing-remitting multiple sclerosis patient cohort from Australia.
    Mult Scler. 2016 Nov 1:1352458516679267. doi: 10.1177/1352458516679267.
    PubMed     Text format     Abstract available


    October 2016
  77. PLANCHE V, Ruet A, Coupe P, Lamargue-Hamel D, et al
    Hippocampal microstructural damage correlates with memory impairment in clinically isolated syndrome suggestive of multiple sclerosis.
    Mult Scler. 2016 Oct 25. pii: 1352458516675750.
    PubMed     Text format     Abstract available


  78. BSTEH G, Feige J, Ehling R, Auer M, et al
    Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors.
    Mult Scler. 2016 Oct 20. pii: 1352458516675751.
    PubMed     Text format     Abstract available


  79. D'AMBROSIO A, Pagani E, Riccitelli GC, Colombo B, et al
    Cerebellar contribution to motor and cognitive performance in multiple sclerosis: An MRI sub-regional volumetric analysis.
    Mult Scler. 2016 Oct 19. pii: 1352458516674567.
    PubMed     Text format     Abstract available


  80. KAVALIUNAS A, Manouchehrinia A, Stawiarz L, Ramanujam R, et al
    Importance of early treatment initiation in the clinical course of multiple sclerosis.
    Mult Scler. 2016 Oct 17. pii: 1352458516675039.
    PubMed     Text format     Abstract available


  81. PIETROBONI AM, Schiano di Cola F, Scarioni M, Fenoglio C, et al
    CSF beta-amyloid as a putative biomarker of disease progression in multiple sclerosis.
    Mult Scler. 2016 Oct 17. pii: 1352458516674566.
    PubMed     Text format     Abstract available


  82. RUANO L, Portaccio E, Goretti B, Niccolai C, et al
    Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes.
    Mult Scler. 2016 Oct 13. pii: 1352458516674367.
    PubMed     Text format     Abstract available


  83. WICKSTROM A, Fagerstrom M, Wickstrom L, Granasen G, et al
    The impact of adjusted work conditions and disease-modifying drugs on work ability in multiple sclerosis.
    Mult Scler. 2016 Oct 6. pii: 1352458516671818.
    PubMed     Text format     Abstract available


  84. AHMAD H, Taylor BV, van der Mei I, Colman S, et al
    The impact of multiple sclerosis severity on health state utility values: Evidence from Australia.
    Mult Scler. 2016 Oct 3. pii: 1352458516672014.
    PubMed     Text format     Abstract available


  85. LUBRINI G, Rios Lago M, Perianez JA, Tallon Barranco A, et al
    The contribution of depressive symptoms to slowness of information processing in relapsing remitting multiple sclerosis.
    Mult Scler. 2016;22:1607-1615.
    PubMed     Text format     Abstract available


  86. ARNETT P
    Lubrini et al.'s study, "The contribution of depressive symptoms to slowness of information processing in relapsing remitting multiple sclerosis".
    Mult Scler. 2016;22:1512-1513.
    PubMed     Text format    


    September 2016
  87. MOBERG JY, Laursen B, Koch-Henriksen N, Thygesen LC, et al
    Employment, disability pension and income for children with parental multiple sclerosis.
    Mult Scler. 2016 Sep 28. pii: 1352458516672016.
    PubMed     Text format     Abstract available


  88. BOESCHOTEN RE, Dekker J, Uitdehaag BM, Beekman AT, et al
    Internet-based treatment for depression in multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2016 Sep 28. pii: 1352458516671820.
    PubMed     Text format     Abstract available


  89. RIBBONS K, Lea R, Tiedeman C, Mackenzie L, et al
    Ongoing increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: A 50-year study.
    Mult Scler. 2016 Sep 28. pii: 1352458516671819.
    PubMed     Text format     Abstract available


  90. SCHLEMM L, Chien C, Bellmann-Strobl J, Dorr J, et al
    Gadopentetate but not gadobutrol accumulates in the dentate nucleus of multiple sclerosis patients.
    Mult Scler. 2016 Sep 27. pii: 1352458516670738.
    PubMed     Text format     Abstract available


  91. GAFSON A, Craner MJ, Matthews PM
    Personalised medicine for multiple sclerosis care.
    Mult Scler. 2016 Sep 26. pii: 1352458516672017.
    PubMed     Text format     Abstract available


  92. BJORNEVIK K, Riise T, Bostrom I, Casetta L, et al
    Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study.
    Mult Scler. 2016 Sep 23. pii: 1352458516671028.
    PubMed     Text format     Abstract available


  93. COLLIGAN E, Metzler A, Tiryaki E
    Shared decision-making in multiple sclerosis: A review.
    Mult Scler. 2016 Sep 23. pii: 1352458516671204.
    PubMed     Text format     Abstract available


  94. HENGSTMAN GJ
    Controversies in MS: All relapsing multiple sclerosis patients should be managed at a specialist clinic - Combine the best of two worlds!
    Mult Scler. 2016 Sep 21. pii: 1352458516670737.
    PubMed     Text format    


  95. LANDFELDT E, Castelo-Branco A, Svedbom A, Lofroth E, et al
    Sick leave and disability pension before and after diagnosis of multiple sclerosis.
    Mult Scler. 2016 Sep 20. pii: 1352458516667567.
    PubMed     Text format     Abstract available


  96. CHOI IY, Lee P, Hughes AJ, Denney DR, et al
    Longitudinal changes of cerebral glutathione (GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis.
    Mult Scler. 2016 Sep 12. pii: 1352458516669441.
    PubMed     Text format     Abstract available


  97. ORPEZ-ZAFRA T, Pavia J, Hurtado-Guerrero I, Pinto-Medel MJ, et al
    Decreased soluble IFN-beta receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker.
    Mult Scler. 2016 Sep 9. pii: 1352458516667564.
    PubMed     Text format     Abstract available


  98. HAKOBYAN S, Luppe S, Evans DR, Harding K, et al
    Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder.
    Mult Scler. 2016 Sep 9. pii: 1352458516669002.
    PubMed     Text format     Abstract available


  99. NELSON F, Akhtar MA, Zuniga E, Perez CA, et al
    Novel fMRI working memory paradigm accurately detects cognitive impairment in multiple sclerosis.
    Mult Scler. 2016 Sep 9. pii: 1352458516666186.
    PubMed     Text format     Abstract available


  100. GRYTTEN N, Skar AB, Aarseth JH, Assmus J, et al
    The influence of coping styles on long-term employment in multiple sclerosis: A prospective study.
    Mult Scler. 2016 Sep 6. pii: 1352458516667240.
    PubMed     Text format     Abstract available


  101. TOURBAH A, Lebrun-Frenay C, Edan G, Clanet M, et al
    MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.
    Mult Scler. 2016 Sep 1. pii: 1352458516667568.
    PubMed     Text format     Abstract available


  102. MUKHOPADHYAY S, Fellows K, Browne RW, Khare P, et al
    Interdependence of oxysterols with cholesterol profiles in multiple sclerosis.
    Mult Scler. 2016 Sep 1. pii: 1352458516666187.
    PubMed     Text format     Abstract available


    August 2016
  103. TROJAN DA, Cybulsky AV
    Drinking away fatigue in multiple sclerosis.
    Mult Scler. 2016 Aug 19. pii: 1352458516666337.
    PubMed     Text format    


  104. CINCOTTA MC, Engelhard MM, Stankey M, Goldman MD, et al
    Fatigue and fluid hydration status in multiple sclerosis: A hypothesis.
    Mult Scler. 2016 Aug 19. pii: 1352458516663854.
    PubMed     Text format     Abstract available


  105. MATHIAS A, Perriard G, Canales M, Soneson C, et al
    Increased ex vivo antigen presentation profile of B cells in multiple sclerosis.
    Mult Scler. 2016 Aug 8. pii: 1352458516664210.
    PubMed     Text format     Abstract available


  106. LANZA G, Ferri R, Bella R, Ferini-Strambi L, et al
    The impact of drugs for multiple sclerosis on sleep.
    Mult Scler. 2016 Aug 8. pii: 1352458516664034.
    PubMed     Text format     Abstract available


  107. KHAN O, Rieckmann P, Boyko A, Selmaj K, et al
    Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
    Mult Scler. 2016 Aug 8. pii: 1352458516664033.
    PubMed     Text format     Abstract available


  108. KIM HJ, Lee J
    Response to letter regarding article 'Comparison of myelin water fraction values in periventricular white matter lesions between multiple sclerosis and neuromyelitis optica spectrum disorder'.
    Mult Scler. 2016 Aug 5. pii: 1352458516662730.
    PubMed     Text format    


  109. POMPA A, Morone G, Iosa M, Pace L, et al
    Does robot-assisted gait training improve ambulation in highly disabled multiple sclerosis people? A pilot randomized control trial.
    Mult Scler. 2016 Aug 2. pii: 1352458516663033.
    PubMed     Text format     Abstract available


  110. KALINCIK T, Kuhle J, Pucci E, Rojas JI, et al
    Data quality evaluation for observational multiple sclerosis registries.
    Mult Scler. 2016 Aug 1. pii: 1352458516662728.
    PubMed     Text format     Abstract available


  111. BOUTIERE C, Rey C, Zaaraoui W, Le Troter A, et al
    Improvement of spasticity following intermittent theta burst stimulation in multiple sclerosis is associated with modulation of resting-state functional connectivity of the primary motor cortices.
    Mult Scler. 2016 Aug 1. pii: 1352458516661640.
    PubMed     Text format     Abstract available


  112. KHOURY SJ, Rochon J, Ding L, Byron M, et al
    ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis.
    Mult Scler. 2016 Aug 1. pii: 1352458516662727.
    PubMed     Text format     Abstract available


  113. SCHREIBER K, Magyari M, Sellebjerg F, Iversen P, et al
    High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
    Mult Scler. 2016 Aug 1. pii: 1352458516661048.
    PubMed     Text format     Abstract available


  114. GROSS CC, Schulte-Mecklenbeck A, Hanning U, Posevitz-Fejfar A, et al
    Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsets.
    Mult Scler. 2016 Aug 1. pii: 1352458516662726.
    PubMed     Text format     Abstract available


    July 2016
  115. BUHLER U, Fleischer V, Luessi F, Rezk A, et al
    Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment.
    Mult Scler. 2016 Jul 19. pii: 1352458516658559.
    PubMed     Text format     Abstract available


  116. ONTANEDA D, Love TE
    Propensity methods for multiple sclerosis: The devil is in the details.
    Mult Scler. 2016 Jul 13. pii: 1352458516660390.
    PubMed     Text format    


  117. SBARDELLA E, Upadhyay N, Tona F, Prosperini L, et al
    Dentate nucleus connectivity in adult patients with multiple sclerosis: functional changes at rest and correlation with clinical features.
    Mult Scler. 2016 Jul 13. pii: 1352458516657438.
    PubMed     Text format     Abstract available


    June 2016
  118. COFRE LIZAMA LE, Khan F, Lee PV, Galea MP, et al
    The use of laboratory gait analysis for understanding gait deterioration in people with multiple sclerosis.
    Mult Scler. 2016 Jun 30. pii: 1352458516658137.
    PubMed     Text format     Abstract available


  119. SOELBERG SORENSEN P, Sellebjerg F
    Neurofilament in CSF-A biomarker of disease activity and long-term prognosis in multiple sclerosis.
    Mult Scler. 2016 Jun 30. pii: 1352458516658560.
    PubMed     Text format    


  120. MCKAY KA, Tremlett H, Patten SB, Fisk JD, et al
    Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.
    Mult Scler. 2016 Jun 29. pii: 1352458516657440.
    PubMed     Text format     Abstract available


  121. VACCHI L, Rocca MA, Meani A, Rodegher M, et al
    Working memory network dysfunction in relapse-onset multiple sclerosis phenotypes: A clinical-imaging evaluation.
    Mult Scler. 2016 Jun 28. pii: 1352458516656809.
    PubMed     Text format     Abstract available


  122. NISHIHARA H, Shimizu F, Kitagawa T, Yamanaka N, et al
    Identification of galectin-3 as a possible antibody target for secondary progressive multiple sclerosis.
    Mult Scler. 2016 Jun 23. pii: 1352458516655217.
    PubMed     Text format     Abstract available


  123. SETHI V, Nair G, Absinta M, Sati P, et al
    Slowly eroding lesions in multiple sclerosis.
    Mult Scler. 2016 Jun 23. pii: 1352458516655403.
    PubMed     Text format     Abstract available


  124. ROSJO E, Lossius A, Abdelmagid N, Lindstrom JC, et al
    Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis.
    Mult Scler. 2016 Jun 20. pii: 1352458516654310.
    PubMed     Text format     Abstract available


  125. MENON S, Zhu F, Shirani A, Oger J, et al
    Disability progression in aggressive multiple sclerosis.
    Mult Scler. 2016 Jun 20. pii: 1352458516653273.
    PubMed     Text format     Abstract available


  126. NAISMITH RT
    Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-NO.
    Mult Scler. 2016 Jun 8. pii: 1352458516644676.
    PubMed     Text format    


  127. MILLER AE
    Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-Commentary.
    Mult Scler. 2016 Jun 8. pii: 1352458516649039.
    PubMed     Text format    


  128. GIOVANNONI G
    Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-YES.
    Mult Scler. 2016 Jun 8. pii: 1352458516650737.
    PubMed     Text format    


  129. BUSCARINU MC, Cerasoli B, Annibali V, Policano C, et al
    Altered intestinal permeability in patients with relapsing-remitting multiple sclerosis: A pilot study.
    Mult Scler. 2016 Jun 6. pii: 1352458516652498.
    PubMed     Text format     Abstract available


  130. CALABRESE M, Castellaro M, Bertoldo A, De Luca A, et al
    Epilepsy in multiple sclerosis: The role of temporal lobe damage.
    Mult Scler. 2016 Jun 3. pii: 1352458516651502.
    PubMed     Text format     Abstract available


    May 2016
  131. FLEISCHER V, Groger A, Koirala N, Droby A, et al
    Increased structural white and grey matter network connectivity compensates for functional decline in early multiple sclerosis.
    Mult Scler. 2016 May 31. pii: 1352458516651503.
    PubMed     Text format     Abstract available


  132. LEE H, Narayanan S, Brown RA, Chen JT, et al
    Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis.
    Mult Scler. 2016 May 31. pii: 1352458516650992.
    PubMed     Text format     Abstract available


  133. VISTBAKKA J, Elovaara I, Lehtimaki T, Hagman S, et al
    Circulating microRNAs as biomarkers in progressive multiple sclerosis.
    Mult Scler. 2016 May 31. pii: 1352458516651141.
    PubMed     Text format     Abstract available


  134. CONWAY DS, Thompson NR, Cohen JA
    Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course.
    Mult Scler. 2016 May 26. pii: 1352458516650512.
    PubMed     Text format     Abstract available


  135. BARONCINI D, Ghezzi A, Annovazzi PO, Colombo B, et al
    Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Mult Scler. 2016 May 26. pii: 1352458516650736.
    PubMed     Text format     Abstract available


  136. OTERO-ROMERO S, Sastre-Garriga J, Comi G, Hartung HP, et al
    Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
    Mult Scler. 2016 May 19. pii: 1352458516643600.
    PubMed     Text format     Abstract available


  137. LIU G, Zhang F, Jiang Y, Hu Y, et al
    Integrating genome-wide association studies and gene expression data highlights dysregulated multiple sclerosis risk pathways.
    Mult Scler. 2016 May 19. pii: 1352458516649038.
    PubMed     Text format     Abstract available


  138. GOLD R, Arnold DL, Bar-Or A, Hutchinson M, et al
    Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.
    Mult Scler. 2016 May 19. pii: 1352458516649037.
    PubMed     Text format     Abstract available


  139. COSTA SL, Genova HM, DeLuca J, Chiaravalloti ND, et al
    Information processing speed in multiple sclerosis: Past, present, and future.
    Mult Scler. 2016 May 9. pii: 1352458516645869.
    PubMed     Text format     Abstract available


  140. BJORNEVIK K, Riise T, Benjaminsen E, Celius EG, et al
    Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study.
    Mult Scler. 2016 May 5. pii: 1352458516646863.
    PubMed     Text format     Abstract available


  141. MILLER AE
    Multiple sclerosis disease-modifying therapy and pregnancy.
    Mult Scler. 2016;22:715-6.
    PubMed     Text format    


    April 2016
  142. PAPATHEMELI D, Grafe R, Hildebrandt U, Zettl UK, et al
    Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod.
    Mult Scler. 2016 Apr 26. pii: 1352458516645868.
    PubMed     Text format     Abstract available


  143. HUTCHINSON M
    All relapsing multiple sclerosis patients should be managed at a specialist clinic - Commentary.
    Mult Scler. 2016 Apr 22. pii: 1352458516646466.
    PubMed     Text format    


  144. BRENNER R
    All relapsing multiple sclerosis patients should be seen in specialist clinics - NO.
    Mult Scler. 2016 Apr 22. pii: 1352458516642855.
    PubMed     Text format    


  145. BROWNLEE WJ, Ciccarelli O
    All relapsing multiple sclerosis patients should be managed at a specialist clinic - YES.
    Mult Scler. 2016 Apr 22. pii: 1352458516636474.
    PubMed     Text format    


  146. LUDWIN SK, Rao VT, Moore CS, Antel JP, et al
    Astrocytes in multiple sclerosis.
    Mult Scler. 2016 Apr 19. pii: 1352458516643396.
    PubMed     Text format     Abstract available


  147. SASTRE-GARRIGA J
    Leptomeningeal enhancement in Susac's syndrome and multiple sclerosis: Time to expect the unexpected?
    Mult Scler. 2016 Apr 18. pii: 1352458516644677.
    PubMed     Text format     Abstract available


  148. VELDHUIJZEN VAN ZANTEN JJ, Pilutti LA, Duda JL, Motl RW, et al
    Sedentary behaviour in people with multiple sclerosis: Is it time to stand up against MS?
    Mult Scler. 2016 Apr 12. pii: 1352458516644340.
    PubMed     Text format     Abstract available


  149. WESTERLIND H, Stawiarz L, Fink K, Hillert J, et al
    A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study.
    Mult Scler. 2016 Apr 12. pii: 1352458516643394.
    PubMed     Text format     Abstract available


  150. BEAUCHEMINA P, Carruthers R
    Response to: Tocilizumab, neuromyelitis optica (NMO), and multiple sclerosis.
    Mult Scler. 2016 Apr 11. pii: 1352458516643398.
    PubMed     Text format    


  151. KOCH-HENRIKSEN N, Magyari M, Sellebjerg F, Soelberg Sorensen P, et al
    A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
    Mult Scler. 2016 Apr 7. pii: 1352458516643393.
    PubMed     Text format     Abstract available


  152. STEWART T, Spelman T, Havrdova E, Horakova D, et al
    Contribution of different relapse phenotypes to disability in multiple sclerosis.
    Mult Scler. 2016 Apr 7. pii: 1352458516643392.
    PubMed     Text format     Abstract available


  153. SEEBACHER B, Kuisma R, Glynn A, Berger T, et al
    The effect of rhythmic-cued motor imagery on walking, fatigue and quality of life in people with multiple sclerosis: A randomised controlled trial.
    Mult Scler. 2016 Apr 7. pii: 1352458516644058.
    PubMed     Text format     Abstract available


  154. UHER T, Vaneckova M, Sobisek L, Tyblova M, et al
    Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis.
    Mult Scler. 2016 Apr 6. pii: 1352458516642314.
    PubMed     Text format     Abstract available


  155. MATOULA T, Nikolaou V, Marinos L, Katsavos S, et al
    Lymphomatoid papulosis type D in a fingolimod-treated multiple sclerosis patient.
    Mult Scler. 2016 Apr 6. pii: 1352458516642032.
    PubMed     Text format    


  156. HARDY TA, Tobin WO, Lucchinetti CF
    Exploring the overlap between multiple sclerosis, tumefactive demyelination and Balo's concentric sclerosis.
    Mult Scler. 2016 Apr 1. pii: 1352458516641776.
    PubMed     Text format     Abstract available


  157. HANKEN K, Eling P, Hildebrandt H
    Is there a cognitive signature for MS-related fatigue? Response to Feinstein.
    Mult Scler. 2016;22:575-6.
    PubMed     Text format    


  158. RACCA V, Di Rienzo M, Cavarretta R, Toccafondi A, et al
    Response to letter regarding article 'Fingolimod effects on left ventricular function in multiple sclerosis'.
    Mult Scler. 2016;22:708-9.
    PubMed     Text format    


  159. MODVIG S, Degn M, Sander B, Horwitz H, et al
    Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis.
    Mult Scler. 2016;22:590-8.
    PubMed     Text format     Abstract available


  160. HADHOUM N, Hodel J, Defoort-Dhellemmes S, Duhamel A, et al
    Length of optic nerve double inversion recovery hypersignal is associated with retinal axonal loss.
    Mult Scler. 2016;22:649-58.
    PubMed     Text format     Abstract available


  161. NEMECEK A, Zimmermann H, Rubenthaler J, Fleischer V, et al
    Flow cytometric analysis of T cell/monocyte ratio in clinically isolated syndrome identifies patients at risk of rapid disease progression.
    Mult Scler. 2016;22:483-93.
    PubMed     Text format     Abstract available


    March 2016
  162. PATEL VP, Zambrana A, Walker LA, Herrmann N, et al
    Distraction adds to the cognitive burden in multiple sclerosis.
    Mult Scler. 2016 Mar 24. pii: 1352458516641208.
    PubMed     Text format     Abstract available


  163. STROHM T, Chaudhry B, Willis MA, Shook S, et al
    Reversible cerebral vasoconstriction syndrome associated with interferon beta-1a use for multiple sclerosis.
    Mult Scler. 2016 Mar 24. pii: 1352458516641774.
    PubMed     Text format     Abstract available


  164. CADAVID D, Cohen JA, Freedman MS, Goldman MD, et al
    The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
    Mult Scler. 2016 Mar 22. pii: 1352458516638941.
    PubMed     Text format     Abstract available


  165. NOVAKOVA L, Axelsson M, Khademi M, Zetterberg H, et al
    Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
    Mult Scler. 2016 Mar 21. pii: 1352458516639384.
    PubMed     Text format     Abstract available


  166. MIDAGLIA L, Juega Marino JM, Sastre-Garriga J, Rovira A, et al
    An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy.
    Mult Scler. 2016 Mar 18. pii: 1352458516638557.
    PubMed     Text format     Abstract available


  167. HILZ MJ
    Cardiac stunning as first manifestation of multiple sclerosis: A case report reminding us not to overlook cardiovascular autonomic dysfunction in multiple sclerosis.
    Mult Scler. 2016 Mar 18. pii: 1352458516638559.
    PubMed     Text format     Abstract available


  168. BECKER J, Rolfs A, Karabul N, Berlit P, et al
    D313Y mutation in the differential diagnosis of white matter lesions: Experiences from a multiple sclerosis outpatient clinic.
    Mult Scler. 2016 Mar 18. pii: 1352458516638747.
    PubMed     Text format     Abstract available


  169. PETRACCA M, Cordano C, Cellerino M, Button J, et al
    Retinal degeneration in primary-progressive multiple sclerosis: A role for cortical lesions?
    Mult Scler. 2016 Mar 18. pii: 1352458516637679.
    PubMed     Text format     Abstract available


  170. ALBOR C, du Sautoy T, Kali Vanan N, Turner BP, et al
    Ethnicity and prevalence of multiple sclerosis in east London.
    Mult Scler. 2016 Mar 17. pii: 1352458516638746.
    PubMed     Text format     Abstract available


  171. OBERMANN M, Ruck T, Pfeuffer S, Baum J, et al
    Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
    Mult Scler. 2016 Mar 15. pii: 1352458516638558.
    PubMed     Text format     Abstract available


  172. ZINGER A, Latham SL, Combes V, Byrne S, et al
    Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients.
    Mult Scler. 2016 Mar 1. pii: 1352458516636959.
    PubMed     Text format     Abstract available


  173. BEVER CT JR, Wallin MT
    Tribute to John F. Kurtzke, MD, FACP, FAAN: 1926-2015.
    Mult Scler. 2016;22:267-8.
    PubMed     Text format    


  174. ENZINGER C, Pinter D, Rocca MA, De Luca J, et al
    Longitudinal fMRI studies: Exploring brain plasticity and repair in MS.
    Mult Scler. 2016;22:269-78.
    PubMed     Text format     Abstract available


  175. PEKCEVIK Y, Mitchell CH, Mealy MA, Orman G, et al
    Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging.
    Mult Scler. 2016;22:302-11.
    PubMed     Text format     Abstract available


  176. MAKHANI N, Banwell B, Tellier R, Yea C, et al
    Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination.
    Mult Scler. 2016;22:385-8.
    PubMed     Text format     Abstract available


  177. VAN SCHEPENDOM J, Gielen J, Laton J, Nagels G, et al
    Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail.
    Mult Scler. 2016;22:389-92.
    PubMed     Text format     Abstract available


    February 2016
  178. THIEL S, Langer-Gould A, Rockhoff M, Haghikia A, et al
    Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry.
    Mult Scler. 2016 Feb 26. pii: 1352458516634872.
    PubMed     Text format     Abstract available


  179. D'AMICO E, Leone C, Hayrettin T, Patti F, et al
    Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal.
    Mult Scler. 2016 Feb 26. pii: 1352458516632066.
    PubMed     Text format     Abstract available


  180. KIM SH, Kwak K, Jeong IH, Hyun JW, et al
    Cognitive impairment differs between neuromyelitis optica spectrum disorder and multiple sclerosis.
    Mult Scler. 2016 Feb 26. pii: 1352458516636246.
    PubMed     Text format     Abstract available


  181. FIEST KM, Marrie RA, Jette N, Bennett DA, et al
    The Standards of Reporting of Neurological Disorders (STROND) checklist: Application to multiple sclerosis.
    Mult Scler. 2016 Feb 26. pii: 1352458516634873.
    PubMed     Text format     Abstract available


  182. SUMOWSKI JF, Rocca MA, Leavitt VM, Riccitelli G, et al
    Reading, writing, and reserve: Literacy activities are linked to hippocampal volume and memory in multiple sclerosis.
    Mult Scler. 2016 Feb 26. pii: 1352458516630822.
    PubMed     Text format     Abstract available


  183. WANG Y, Bos SD, Harbo HF, Thompson WK, et al
    Genetic overlap between multiple sclerosis and several cardiovascular disease risk factors.
    Mult Scler. 2016 Feb 26. pii: 1352458516635873.
    PubMed     Text format     Abstract available


  184. JEONG IH, Choi JY, Kim SH, Hyun JW, et al
    Comparison of myelin water fraction values in periventricular white matter lesions between multiple sclerosis and neuromyelitis optica spectrum disorder.
    Mult Scler. 2016 Feb 26. pii: 1352458516636247.
    PubMed     Text format     Abstract available


  185. CAVALLARI M, Palotai M, Glanz BI, Egorova S, et al
    Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2016 Feb 26. pii: 1352458516635874.
    PubMed     Text format     Abstract available


  186. RAZAZ N, Tremlett H, Marrie RA, Joseph KS, et al
    Peripartum depression in parents with multiple sclerosis and psychiatric disorders in children.
    Mult Scler. 2016 Feb 22. pii: 1352458516631037.
    PubMed     Text format     Abstract available


  187. JIANG H, Delgado S, Tan J, Liu C, et al
    Impaired retinal microcirculation in multiple sclerosis.
    Mult Scler. 2016 Feb 22. pii: 1352458516631035.
    PubMed     Text format     Abstract available


  188. SANAI SA, Saini V, Benedict RH, Zivadinov R, et al
    Aging and multiple sclerosis.
    Mult Scler. 2016 Feb 19. pii: 1352458516634871.
    PubMed     Text format     Abstract available


  189. PHE V, Pakzad M, Curtis C, Porter B, et al
    Urinary tract infections in multiple sclerosis.
    Mult Scler. 2016 Feb 18. pii: 1352458516633903.
    PubMed     Text format     Abstract available


  190. DECKER Y, Schomburg R, Nemeth E, Vitkin A, et al
    Abnormal galactosylation of immunoglobulin G in cerebrospinal fluid of multiple sclerosis patients.
    Mult Scler. 2016 Feb 16. pii: 1352458516631036.
    PubMed     Text format     Abstract available


  191. MOKKINK LB, Galindo-Garre F, Uitdehaag BM
    Evaluation of the Multiple Sclerosis Walking Scale-12 (MSWS-12) in a Dutch sample: Application of item response theory.
    Mult Scler. 2016 Feb 12. pii: 1352458516630821.
    PubMed     Text format     Abstract available


  192. SCALFARI A, Lederer C, Daumer M, Nicholas R, et al
    The relationship of age with the clinical phenotype in multiple sclerosis.
    Mult Scler. 2016 Feb 11. pii: 1352458516630396.
    PubMed     Text format     Abstract available


  193. PASTO L, Portaccio E, Goretti B, Ghezzi A, et al
    The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis.
    Mult Scler. 2016 Feb 11. pii: 1352458516629559.
    PubMed     Text format     Abstract available


  194. PAKPOOR J, Wotton CJ, Schmierer K, Giovannoni G, et al
    Gender identity disorders and multiple sclerosis risk: A national record-linkage study.
    Mult Scler. 2016 Feb 8. pii: 1352458515627205.
    PubMed     Text format     Abstract available


  195. BISECCO A, Caiazzo G, d'Ambrosio A, Sacco R, et al
    Fatigue in multiple sclerosis: The contribution of occult white matter damage.
    Mult Scler. 2016 Feb 4. pii: 1352458516628331.
    PubMed     Text format     Abstract available


  196. PRAVATA E, Zecca C, Sestieri C, Caulo M, et al
    Hyperconnectivity of the dorsolateral prefrontal cortex following mental effort in multiple sclerosis patients with cognitive fatigue.
    Mult Scler. 2016 Feb 4. pii: 1352458515625806.
    PubMed     Text format     Abstract available


  197. FAIVRE A, Robinet E, Guye M, Rousseau C, et al
    Depletion of brain functional connectivity enhancement leads to disability progression in multiple sclerosis: A longitudinal resting-state fMRI study.
    Mult Scler. 2016 Feb 2. pii: 1352458516628657.
    PubMed     Text format     Abstract available


  198. TAYLOR BV
    Modeling the course and outcomes of multiple sclerosis is statistical twaddle-Yes.
    Mult Scler. 2016;22:140-2.
    PubMed     Text format    


  199. BERGAMASCHI R, Montomoli C
    Modeling the course and outcomes of MS is statistical twaddle--No.
    Mult Scler. 2016;22:142-4.
    PubMed     Text format    


  200. BEAUCHEMIN P, Carruthers R
    MS arising during Tocilizumab therapy for rheumatoid arthritis.
    Mult Scler. 2016;22:254-6.
    PubMed     Text format     Abstract available


  201. FERNANDEZ-CARBONELL C, Vargas-Lowy D, Musallam A, Healy B, et al
    Clinical and MRI phenotype of children with MOG antibodies.
    Mult Scler. 2016;22:174-84.
    PubMed     Text format     Abstract available


  202. HUPPERTS R, Lycke J, Short C, Gasperini C, et al
    Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
    Mult Scler. 2016;22:212-21.
    PubMed     Text format     Abstract available


    January 2016
  203. LAULE C, Yung A, Pavolva V, Bohnet B, et al
    High-resolution myelin water imaging in post-mortem multiple sclerosis spinal cord: A case report.
    Mult Scler. 2016 Jan 27. pii: 1352458515624559.
    PubMed     Text format     Abstract available


  204. ZHOU Y, Zhu G, Charlesworth JC, Simpson S Jr, et al
    Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis.
    Mult Scler. 2016 Jan 27. pii: 1352458515626598.
    PubMed     Text format     Abstract available


  205. BEHRENS JR, Mertens S, Kruger T, Grobelny A, et al
    Validity of visual perceptive computing for static posturography in patients with multiple sclerosis.
    Mult Scler. 2016 Jan 26. pii: 1352458515625807.
    PubMed     Text format     Abstract available


  206. GEORGE IC, Sati P, Absinta M, Cortese IC, et al
    Clinical 3-tesla FLAIR* MRI improves diagnostic accuracy in multiple sclerosis.
    Mult Scler. 2016 Jan 14. pii: 1352458515624975.
    PubMed     Text format     Abstract available


  207. ZORNER B, Filli L, Reuter K, Kapitza S, et al
    Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.
    Mult Scler. 2016 Jan 13. pii: 1352458515622695.
    PubMed     Text format     Abstract available


  208. KHALIL M, Renner A, Langkammer C, Enzinger C, et al
    Cerebrospinal fluid lipocalin 2 in patients with clinically isolated syndromes and early multiple sclerosis.
    Mult Scler. 2016 Jan 13. pii: 1352458515624560.
    PubMed     Text format     Abstract available


  209. OHRFELT A, Axelsson M, Malmestrom C, Novakova L, et al
    Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
    Mult Scler. 2016 Jan 11. pii: 1352458515624558.
    PubMed     Text format     Abstract available


  210. PANDIT L, Ban M, Beecham AH, McCauley JL, et al
    European multiple sclerosis risk variants in the south Asian population.
    Mult Scler. 2016 Jan 11. pii: 1352458515624270.
    PubMed     Text format     Abstract available


  211. BHARGAVA P, Calabresi PA
    Metabolomics in multiple sclerosis.
    Mult Scler. 2016 Jan 11. pii: 1352458515622827.
    PubMed     Text format     Abstract available


  212. HOJJAT SP, Cantrell CG, Vitorino R, Feinstein A, et al
    Regional reduction in cortical blood flow among cognitively impaired adults with relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2016 Jan 11. pii: 1352458515622696.
    PubMed     Text format     Abstract available


  213. NIELSEN NM, Harpsoe MC, Simonsen J, Stenager E, et al
    Self-rated health in women prior to clinical onset of multiple sclerosis: A study within the Danish National Birth Cohort.
    Mult Scler. 2016 Jan 8. pii: 1352458515621623.
    PubMed     Text format     Abstract available


  214. HASSELMANN H, Bellmann-Strobl J, Ricken R, Oberwahrenbrock T, et al
    Characterizing the phenotype of multiple sclerosis-associated depression in comparison with idiopathic major depression.
    Mult Scler. 2016 Jan 8. pii: 1352458515622826.
    PubMed     Text format     Abstract available


  215. COMABELLA M
    Tocilizumab and multiple sclerosis: a causal relationship? Clinical Commentary on the case report entitled - MS arising during Tocilizumab therapy for rheumatoid arthritis.
    Mult Scler. 2016 Jan 7. pii: 1352458515623863.
    PubMed     Text format     Abstract available


  216. MEIJER KA, Muhlert N, Cercignani M, Sethi V, et al
    White matter tract abnormalities are associated with cognitive dysfunction in secondary progressive multiple sclerosis.
    Mult Scler. 2016 Jan 5. pii: 1352458515622694.
    PubMed     Text format     Abstract available


  217. MORI F, Nistico R, Nicoletti CG, Zagaglia S, et al
    RANTES correlates with inflammatory activity and synaptic excitability in multiple sclerosis.
    Mult Scler. 2016 Jan 5. pii: 1352458515621796.
    PubMed     Text format     Abstract available


  218. SASTRE-GARRIGA J, Wiendl H
    Highlights from the 31st ECTRIMS congress - Barcelona 2015.
    Mult Scler. 2016;22:7-10.
    PubMed     Text format    


  219. REINGOLD SC, Lublin FD
    William Austin Sibley, MD (1925-2015).
    Mult Scler. 2016;22:11-2.
    PubMed     Text format    


  220. FREEDMAN MS
    Are we in need of NEDA?
    Mult Scler. 2016;22:5-6.
    PubMed     Text format    


  221. ZAJDA M, Kazmierczak B, Zakrzewska-Pniewska B
    Aquaporin-4: A novel diagnostic biomarker for seronegative neuromyelitis optica.
    Mult Scler. 2016;22:125-6.
    PubMed     Text format    


    December 2015
  222. RAZAZ N, Joseph KS, Boyce WT, Guhn M, et al
    Children of chronically ill parents: Relationship between parental multiple sclerosis and childhood developmental health.
    Mult Scler. 2015 Dec 18. pii: 1352458515621624.
    PubMed     Text format     Abstract available


  223. JONKMAN LE, Fleysher L, Steenwijk MD, Koeleman JA, et al
    Ultra-high field MTR and qR2* differentiates subpial cortical lesions from normal-appearing gray matter in multiple sclerosis.
    Mult Scler. 2015 Dec 16. pii: 1352458515620499.
    PubMed     Text format     Abstract available


  224. CONTE A, Li Voti P, Pontecorvo S, Quartuccio ME, et al
    Attention-related changes in short-term cortical plasticity help to explain fatigue in multiple sclerosis.
    Mult Scler. 2015 Dec 16. pii: 1352458515619780.
    PubMed     Text format     Abstract available


  225. STRAUDI S, Fanciullacci C, Martinuzzi C, Pavarelli C, et al
    The effects of robot-assisted gait training in progressive multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2015 Dec 10. pii: 1352458515620933.
    PubMed     Text format     Abstract available


  226. MISTRY N, Abdel-Fahim R, Samaraweera A, Mougin O, et al
    Imaging central veins in brain lesions with 3-T T2*-weighted magnetic resonance imaging differentiates multiple sclerosis from microangiopathic brain lesions.
    Mult Scler. 2015 Dec 10. pii: 1352458515616700.
    PubMed     Text format     Abstract available


    November 2015
  227. SCHEEPE JR, Wong YY, van Pelt ED, Ketelslegers IA, et al
    Neurogenic lower urinary tract dysfunction in the early disease phase of paediatric multiple sclerosis.
    Mult Scler. 2015 Nov 20. pii: 1352458515618541.
    PubMed     Text format     Abstract available


  228. KAPPOS L, De Stefano N, Freedman MS, Cree BA, et al
    Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
    Mult Scler. 2015 Nov 19. pii: 1352458515616701.
    PubMed     Text format     Abstract available


  229. STEENWIJK MD, Vrenken H, Jonkman LE, Daams M, et al
    High-resolution T1-relaxation time mapping displays subtle, clinically relevant, gray matter damage in long-standing multiple sclerosis.
    Mult Scler. 2015 Nov 12. pii: 1352458515615953.
    PubMed     Text format     Abstract available


  230. FOK A, Williams T, McLean CA, Butler E, et al
    Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients.
    Mult Scler. 2015 Nov 12. pii: 1352458515618020.
    PubMed     Text format     Abstract available


  231. YAMASAKI R, Matsushita T, Fukazawa T, Yokoyama K, et al
    Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica.
    Mult Scler. 2015 Nov 12. pii: 1352458515617248.
    PubMed     Text format     Abstract available


  232. HUTCHINSON M
    Neurodegeneration in multiple sclerosis is a process separate from inflammation: No.
    Mult Scler. 2015;21:1628-31.
    PubMed     Text format    


  233. LOUAPRE C, Lubetzki C
    Neurodegeneration in multiple sclerosis is a process separate from inflammation: Yes.
    Mult Scler. 2015;21:1626-8.
    PubMed     Text format    


    October 2015
  234. WILLIS MD, Harding KE, Pickersgill TP, Wardle M, et al
    Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.
    Mult Scler. 2015 Oct 29. pii: 1352458515614092.
    PubMed     Text format     Abstract available


  235. UDDIN MN, Lebel RM, Seres P, Blevins G, et al
    Spin echo transverse relaxation and atrophy in multiple sclerosis deep gray matter: A two-year longitudinal study.
    Mult Scler. 2015 Oct 26. pii: 1352458515614091.
    PubMed     Text format     Abstract available


  236. AHLBRECHT J, Martino F, Pul R, Skripuletz T, et al
    Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis.
    Mult Scler. 2015 Oct 22. pii: 1352458515613641.
    PubMed     Text format     Abstract available


  237. ROCCA MA, Meani A, Riccitelli GC, Colombo B, et al
    Abnormal adaptation over time of motor network recruitment in multiple sclerosis patients with fatigue.
    Mult Scler. 2015 Oct 22. pii: 1352458515614407.
    PubMed     Text format     Abstract available


  238. HEITMANN H, Biberacher V, Tiemann L, Buck D, et al
    Prevalence of neuropathic pain in early multiple sclerosis.
    Mult Scler. 2015 Oct 19. pii: 1352458515613643.
    PubMed     Text format     Abstract available


  239. LANZILLO R, Quarantelli M, Pozzilli C, Trojano M, et al
    No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon beta1a therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
    Mult Scler. 2015 Oct 14. pii: 1352458515611222.
    PubMed     Text format     Abstract available


  240. KARAKY M, Alcina A, Fedetz M, Barrionuevo C, et al
    The multiple sclerosis-associated regulatory variant rs10877013 affects expression of CYP27B1 and VDR under inflammatory or vitamin D stimuli.
    Mult Scler. 2015 Oct 14. pii: 1352458515610208.
    PubMed     Text format     Abstract available


  241. SANDBERG L, Bistrom M, Salzer J, Vagberg M, et al
    Vitamin D and axonal injury in multiple sclerosis.
    Mult Scler. 2015 Oct 13. pii: 1352458515606986.
    PubMed     Text format     Abstract available


  242. HEDSTROM AK, Olsson T, Alfredsson L
    Smoking is a major preventable risk factor for multiple sclerosis.
    Mult Scler. 2015 Oct 12. pii: 1352458515609794.
    PubMed     Text format     Abstract available


  243. LONGBRAKE EE, Ramsbottom MJ, Cantoni C, Ghezzi L, et al
    Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
    Mult Scler. 2015 Oct 12. pii: 1352458515608961.
    PubMed     Text format     Abstract available


  244. ZECCA C, Disanto G, Sormani MP, Riccitelli GC, et al
    Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis.
    Mult Scler. 2015 Oct 12. pii: 1352458515599246.
    PubMed     Text format     Abstract available


  245. AKHTAR S, Alroughani R, Ahmed SF, Al-Hashel JY, et al
    Prognostic indicators of secondary progression in a paediatric-onset multiple sclerosis cohort in Kuwait.
    Mult Scler. 2015 Oct 9. pii: 1352458515608960.
    PubMed     Text format     Abstract available


  246. SIGNORIELLO E, Lanzillo R, Brescia Morra V, Di Iorio G, et al
    Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis.
    Mult Scler. 2015 Oct 9. pii: 1352458515604381.
    PubMed     Text format     Abstract available


  247. EISELE P, Konstandin S, Griebe M, Szabo K, et al
    Heterogeneity of acute multiple sclerosis lesions on sodium (23Na) MRI.
    Mult Scler. 2015 Oct 9. pii: 1352458515609430.
    PubMed     Text format     Abstract available


  248. RICCELLI R, Passamonti L, Cerasa A, Nigro S, et al
    Individual differences in depression are associated with abnormal function of the limbic system in multiple sclerosis patients.
    Mult Scler. 2015 Oct 9. pii: 1352458515606987.
    PubMed     Text format     Abstract available


  249. DEGN M, Modvig S, Dyring-Andersen B, Bonefeld CM, et al
    Increased prevalence of lymphoid tissue inducer cells in the cerebrospinal fluid of patients with early multiple sclerosis.
    Mult Scler. 2015 Oct 9. pii: 1352458515609795.
    PubMed     Text format     Abstract available


  250. STRUPP J, Voltz R, Golla H
    Opening locked doors: Integrating a palliative care approach into the management of patients with severe multiple sclerosis.
    Mult Scler. 2015 Oct 7. pii: 1352458515608262.
    PubMed     Text format     Abstract available


  251. MACDONELL R, Nagels G, Laplaud DA, Pozzilli C, et al
    Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
    Mult Scler. 2015 Oct 7. pii: 1352458515606809.
    PubMed     Text format     Abstract available


  252. TOBIN WO, Popescu BF, Lowe V, Pirko I, et al
    Multiple sclerosis masquerading as Alzheimer-type dementia: Clinical, radiological and pathological findings.
    Mult Scler. 2015 Oct 7. pii: 1352458515604382.
    PubMed     Text format     Abstract available


  253. HUCKE S, Wiendl H, Klotz L
    Implications of dietary salt intake for multiple sclerosis pathogenesis.
    Mult Scler. 2015 Oct 7. pii: 1352458515609431.
    PubMed     Text format     Abstract available


  254. BOVE R, Healy BC, Musallam A, Glanz BI, et al
    Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort.
    Mult Scler. 2015 Oct 7. pii: 1352458515606211.
    PubMed     Text format     Abstract available


  255. VERCELLINO M, Fenoglio C, Galimberti D, Mattioda A, et al
    Progranulin genetic polymorphisms influence progression of disability and relapse recovery in multiple sclerosis.
    Mult Scler. 2015 Oct 7. pii: 1352458515610646.
    PubMed     Text format     Abstract available


  256. YEH EA, Kinnett-Hopkins D, Grover SA, Motl RW, et al
    Physical activity and pediatric multiple sclerosis: Developing a research agenda.
    Mult Scler. 2015 Oct 7. pii: 1352458515606526.
    PubMed     Text format     Abstract available


  257. TILLEMA JM, Hulst HE, Rocca MA, Vrenken H, et al
    Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study.
    Mult Scler. 2015 Oct 2. pii: 1352458515607650.
    PubMed     Text format     Abstract available


  258. RATZER R, Iversen P, Bornsen L, Dyrby TB, et al
    Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis.
    Mult Scler. 2015 Oct 2. pii: 1352458515605908.
    PubMed     Text format     Abstract available


  259. ALLA S, Pearson JF, Taylor BV, Roxburgh R, et al
    An investigation of the relationship between latitude and multiple sclerosis severity in New Zealand.
    Mult Scler. 2015 Oct 2. pii: 1352458515605909.
    PubMed     Text format    


  260. DAMASCENO A, Damasceno BP, Cendes F
    No evidence of disease activity in multiple sclerosis: Implications on cognition and brain atrophy.
    Mult Scler. 2015 Oct 2. pii: 1352458515604383.
    PubMed     Text format     Abstract available


  261. KEARNEY H, Miszkiel KA, Yiannakas MC, Altmann DR, et al
    Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis.
    Mult Scler. 2015 Oct 2. pii: 1352458515604905.
    PubMed     Text format     Abstract available


  262. COSTA C, Martinez-Saez E, Gutierrez-Franco A, Eixarch H, et al
    Expression of semaphorin 3A, semaphorin 7A and their receptors in multiple sclerosis lesions.
    Mult Scler. 2015 Oct 2. pii: 1352458515599848.
    PubMed     Text format     Abstract available


  263. BARIZZONE N, Zara I, Sorosina M, Lupoli S, et al
    The burden of multiple sclerosis variants in continental Italians and Sardinians.
    Mult Scler. 2015;21:1385-95.
    PubMed     Text format     Abstract available


  264. HUTCHINSON M
    Multiple sclerosis relapse phenotype is an important, neglected determinant of disease-outcome: Commentary.
    Mult Scler. 2015;21:1374-5.
    PubMed     Text format    


  265. SCALFARI A
    Multiple sclerosis relapse phenotype is an important, neglected, determinant of disease outcome - NO.
    Mult Scler. 2015;21:1371-4.
    PubMed     Text format    


  266. SCOTT TF
    Multiple sclerosis relapse phenotype is an important, neglected, determinant of disease outcome - YES.
    Mult Scler. 2015;21:1369-71.
    PubMed     Text format    


    September 2015
  267. SIMULA S, Laitinen T, Laitinen TM, Tarkiainen T, et al
    Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis.
    Mult Scler. 2015 Sep 11. pii: 1352458515604384.
    PubMed     Text format     Abstract available


  268. GUTTMANN CR, Rousset M, Roch JA, Hannoun S, et al
    Multiple sclerosis lesion formation and early evolution revisited: A weekly high-resolution magnetic resonance imaging study.
    Mult Scler. 2015 Sep 11. pii: 1352458515600247.
    PubMed     Text format     Abstract available


  269. KUHLE J, Hardmeier M, Disanto G, Gugleta K, et al
    A 10-year follow-up of the European multicenter trial of interferon beta-1b in secondary-progressive multiple sclerosis.
    Mult Scler. 2015 Sep 11. pii: 1352458515594440.
    PubMed     Text format     Abstract available


  270. MARTINEZ-RODRIGUEZ JE, Cobo-Calvo A, Villar LM, Munteis E, et al
    Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis.
    Mult Scler. 2015 Sep 11. pii: 1352458515601215.
    PubMed     Text format     Abstract available


  271. MOCCIA M, Lanzillo R, Palladino R, Chang KC, et al
    Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression.
    Mult Scler. 2015 Sep 11. pii: 1352458515599075.
    PubMed     Text format     Abstract available


  272. UHER T, Horakova D, Tyblova M, Zeman D, et al
    Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.
    Mult Scler. 2015 Sep 11. pii: 1352458515601903.
    PubMed     Text format     Abstract available


  273. SEPULVEDA M, Ros C, Martinez-Lapiscina EH, Sola-Valls N, et al
    Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study.
    Mult Scler. 2015 Sep 11. pii: 1352458515602339.
    PubMed     Text format     Abstract available


  274. BINZER S, Stenager E, Binzer M, Kyvik KO, et al
    Genetic analysis of the isolated Faroe Islands reveals SORCS3 as a potential multiple sclerosis risk gene.
    Mult Scler. 2015 Sep 11. pii: 1352458515602338.
    PubMed     Text format     Abstract available


  275. BAKSHI R, Haring DA
    Comment on "Fingolimod effects on left ventricular function in multiple sclerosis" Mult Scler 2015.
    Mult Scler. 2015 Sep 10. pii: 1352458515600250.
    PubMed     Text format    


    August 2015
  276. ROCCA MA, Morelli ME, Amato MP, Moiola L, et al
    Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis.
    Mult Scler. 2015 Aug 18. pii: 1352458515598569.
    PubMed     Text format     Abstract available


  277. PLEMEL JR, Juzwik CA, Benson CA, Monks M, et al
    Over-the-counter anti-oxidant therapies for use in multiple sclerosis: A systematic review.
    Mult Scler. 2015 Aug 18. pii: 1352458515601513.
    PubMed     Text format     Abstract available


  278. GONSETTE R, Debouverie M, Sindic C, Ferre JC, et al
    Pixantrone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease.
    Mult Scler. 2015 Aug 18. pii: 1352458515601902.
    PubMed     Text format     Abstract available


  279. BHARGAVA P, Steele SU, Waubant E, Revirajan NR, et al
    Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls.
    Mult Scler. 2015 Aug 18. pii: 1352458515600248.
    PubMed     Text format     Abstract available


  280. KRAEMER M, Weber R, Herold M, Berlit P, et al
    Reversible cerebral vasoconstriction syndrome associated with fingolimod treatment in relapsing-remitting multiple sclerosis three months after childbirth.
    Mult Scler. 2015 Aug 17. pii: 1352458515600249.
    PubMed     Text format     Abstract available


  281. TACCONI P, Peltz MT, Lorefice L, Marrosu MG, et al
    Facial synkinesis as a first symptom of multiple sclerosis.
    Mult Scler. 2015 Aug 5. pii: 1352458515584415.
    PubMed     Text format     Abstract available


  282. MCKAY KA, Tremlett H, Fisk JD, Patten SB, et al
    Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: A prospective multisite study.
    Mult Scler. 2015 Aug 5. pii: 1352458515599073.
    PubMed     Text format     Abstract available


  283. HUTCHINSON M
    The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level: Commentary.
    Mult Scler. 2015 Aug 4. pii: 1352458515599682.
    PubMed     Text format    


  284. ARRAMBIDE G, Espejo C, Tintore M
    The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level-NO.
    Mult Scler. 2015 Aug 4. pii: 1352458515589774.
    PubMed     Text format    


  285. MILLER DM, Bethoux F, Victorson D, Nowinski CJ, et al
    Validating Neuro-QoL short forms and targeted scales with people who have multiple sclerosis.
    Mult Scler. 2015 Aug 3. pii: 1352458515599450.
    PubMed     Text format     Abstract available


  286. FISHER E, Nakamura K, Lee JC, You X, et al
    Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.
    Mult Scler. 2015 Aug 3. pii: 1352458515599072.
    PubMed     Text format     Abstract available


  287. COHEN M, Lebrun C, Ayrignac X, Labauge P, et al
    Solitary sclerosis: Experience from three French tertiary care centres.
    Mult Scler. 2015;21:1216.
    PubMed     Text format    


    July 2015
  288. CHILCOT J, Norton S, Kelly ME, Moss-Morris R, et al
    The Chalder Fatigue Questionnaire is a valid and reliable measure of perceived fatigue severity in multiple sclerosis.
    Mult Scler. 2015 Jul 31. pii: 1352458515598019.
    PubMed     Text format     Abstract available


  289. ROY S, Rodgers J, Drake AS, Zivadinov R, et al
    Stable neuropsychiatric status in multiple sclerosis: a 3-year study.
    Mult Scler. 2015 Jul 30. pii: 1352458515597570.
    PubMed     Text format     Abstract available


  290. SAMARAWEERA AP, Cohen SN, Akay EM, Evangelou N, et al
    Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
    Mult Scler. 2015 Jul 28. pii: 1352458515597568.
    PubMed     Text format     Abstract available


  291. DAAMS M, Steenwijk MD, Schoonheim MM, Wattjes MP, et al
    Multi-parametric structural magnetic resonance imaging in relation to cognitive dysfunction in long-standing multiple sclerosis.
    Mult Scler. 2015 Jul 24. pii: 1352458515596598.
    PubMed     Text format     Abstract available


  292. DULA AN, Pawate S, Dortch RD, Barry RL, et al
    Magnetic resonance imaging of the cervical spinal cord in multiple sclerosis at 7T.
    Mult Scler. 2015 Jul 24. pii: 1352458515591070.
    PubMed     Text format     Abstract available


  293. WEIER K, Till C, Fonov V, Yeh EA, et al
    Contribution of the cerebellum to cognitive performance in children and adolescents with multiple sclerosis.
    Mult Scler. 2015 Jul 22. pii: 1352458515595132.
    PubMed     Text format     Abstract available


  294. ROCCA MA, Sonkin M, Copetti M, Pagani E, et al
    Diffusion tensor magnetic resonance imaging in very early onset pediatric multiple sclerosis.
    Mult Scler. 2015 Jul 21. pii: 1352458515596600.
    PubMed     Text format     Abstract available


  295. GERSCHENFELD G, Servy A, Valeyrie-Allanore L, de Prost N, et al
    Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
    Mult Scler. 2015 Jul 21. pii: 1352458515596601.
    PubMed     Text format     Abstract available


  296. HILVEN K, Goris A
    Genetic burden mirrors epidemiology of multiple sclerosis.
    Mult Scler. 2015 Jul 21. pii: 1352458515596603.
    PubMed     Text format    


  297. VAN DER MEI I, Lucas RM, Taylor BV, Valery PC, et al
    Population attributable fractions and joint effects of key risk factors for multiple sclerosis.
    Mult Scler. 2015 Jul 21. pii: 1352458515594040.
    PubMed     Text format     Abstract available


  298. PRESSLAUER S, Milosavljevic D, Huebl W, Aboulenein-Djamshidian F, et al
    Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: A multicenter study.
    Mult Scler. 2015 Jul 21. pii: 1352458515594044.
    PubMed     Text format     Abstract available


  299. WARRENDER-SPARKES M, Spelman T, Izquierdo G, Trojano M, et al
    The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
    Mult Scler. 2015 Jul 21. pii: 1352458515594041.
    PubMed     Text format     Abstract available


  300. NUNAN-SAAH J, Paulraj SR, Waubant E, Krupp LB, et al
    Neuropsychological correlates of multiple sclerosis across the lifespan.
    Mult Scler. 2015 Jul 10. pii: 1352458515586088.
    PubMed     Text format     Abstract available


  301. PICHLER A, Khalil M, Langkammer C, Pinter D, et al
    Combined analysis of global and compartmental brain volume changes in early multiple sclerosis in clinical practice.
    Mult Scler. 2015 Jul 10. pii: 1352458515593405.
    PubMed     Text format     Abstract available


  302. GOVEROVER Y, Chiaravalloti N, DeLuca J
    Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) and performance of everyday life tasks: Actual Reality.
    Mult Scler. 2015 Jul 10. pii: 1352458515593637.
    PubMed     Text format     Abstract available


  303. FAVARETTO A, Lazzarotto A, Poggiali D, Rolma G, et al
    MRI-detectable cortical lesions in the cerebellum and their clinical relevance in multiple sclerosis.
    Mult Scler. 2015 Jul 10. pii: 1352458515594043.
    PubMed     Text format     Abstract available


  304. CIRILLO S, Rocca MA, Ghezzi A, Valsasina P, et al
    Abnormal cerebellar functional MRI connectivity in patients with paediatric multiple sclerosis.
    Mult Scler. 2015 Jul 10. pii: 1352458515592191.
    PubMed     Text format     Abstract available


  305. RAMANATHAN S, Prelog K, Barnes EH, Tantsis EM, et al
    Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.
    Mult Scler. 2015 Jul 10. pii: 1352458515593406.
    PubMed     Text format     Abstract available


  306. ZARBO IR, Minacapelli E, Falautano M, Demontis S, et al
    Personality traits predict perceived health-related quality of life in persons with multiple sclerosis.
    Mult Scler. 2015 Jul 10. pii: 1352458515594045.
    PubMed     Text format     Abstract available


    June 2015
  307. 'T HART BA
    Why does multiple sclerosis only affect human primates?
    Mult Scler. 2015 Jun 25. pii: 1352458515591862.
    PubMed     Text format     Abstract available


  308. RAMO-TELLO C, Tintore M, Rovira A, Ramio-Torrenta L, et al
    Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses.
    Mult Scler. 2015 Jun 25. pii: 1352458515590648.
    PubMed     Text format     Abstract available


  309. HERTWIG L, Pache F, Romero-Suarez S, Sturner KH, et al
    Distinct functionality of neutrophils in multiple sclerosis and neuromyelitis optica.
    Mult Scler. 2015 Jun 25. pii: 1352458515586084.
    PubMed     Text format     Abstract available


  310. KOENIG KA, Sakaie KE, Lowe MJ, Lin J, et al
    The relationship between cognitive function and high-resolution diffusion tensor MRI of the cingulum bundle in multiple sclerosis.
    Mult Scler. 2015 Jun 23. pii: 1352458515576983.
    PubMed     Text format     Abstract available


  311. FAINARDI E, Bortolotti D, Bolzani S, Castellazzi M, et al
    Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis.
    Mult Scler. 2015 Jun 17. pii: 1352458515590647.
    PubMed     Text format     Abstract available


  312. HUGHES SE, Gray OM
    Symptomatic therapy in multiple sclerosis: Big pharma should do more - NO.
    Mult Scler. 2015 Jun 17. pii: 1352458515587930.
    PubMed     Text format    


  313. SIVA A, Kantarci O
    Symptomatic therapy in multiple sclerosis: Big pharma should do more-YES.
    Mult Scler. 2015 Jun 17. pii: 1352458515588974.
    PubMed     Text format    


  314. HUTCHINSON M
    Symptomatic therapy in multiple sclerosis: Big pharma should do more - commentary.
    Mult Scler. 2015 Jun 17. pii: 1352458515590281.
    PubMed     Text format    


  315. HOANG H, Laursen B, Stenager EN, Stenager E, et al
    Psychiatric co-morbidity in multiple sclerosis: The risk of depression and anxiety before and after MS diagnosis.
    Mult Scler. 2015 Jun 3. pii: 1352458515588973.
    PubMed     Text format     Abstract available


  316. BARUCH NF, O'Donnell EH, Glanz BI, Benedict RH, et al
    Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosis.
    Mult Scler. 2015 Jun 3. pii: 1352458515588781.
    PubMed     Text format     Abstract available


  317. SBARDELLA E, Tona F, Petsas N, Upadhyay N, et al
    Functional connectivity changes and their relationship with clinical disability and white matter integrity in patients with relapsing-remitting multiple sclerosis.
    Mult Scler. 2015 Jun 3. pii: 1352458514568826.
    PubMed     Text format     Abstract available


  318. THEAUDIN M, Romero K, Feinstein A
    In multiple sclerosis anxiety, not depression, is related to gender.
    Mult Scler. 2015 Jun 3. pii: 1352458515588582.
    PubMed     Text format     Abstract available


  319. VAN NIEROP GP, Mautner J, Mitterreiter JG, Hintzen RQ, et al
    Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins.
    Mult Scler. 2015 Jun 3. pii: 1352458515588581.
    PubMed     Text format     Abstract available


  320. CICCARELLI O, Toosy AT
    Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.
    Mult Scler. 2015 Jun 3. pii: 1352458515588583.
    PubMed     Text format    


  321. RACCA V, Di Rienzo M, Cavarretta R, Toccafondi A, et al
    Fingolimod effects on left ventricular function in multiple sclerosis.
    Mult Scler. 2015 Jun 3. pii: 1352458515587753.
    PubMed     Text format     Abstract available


    May 2015
  322. YALDIZLI O, Pardini M, Sethi V, Muhlert N, et al
    Characteristics of lesional and extra-lesional cortical grey matter in relapsing-remitting and secondary progressive multiple sclerosis: A magnetisation transfer and diffusion tensor imaging study.
    Mult Scler. 2015 May 26. pii: 1352458515586085.
    PubMed     Text format     Abstract available


  323. HEINE M, Wens I, Langeskov-Christensen M, Verschuren O, et al
    Cardiopulmonary fitness is related to disease severity in multiple sclerosis.
    Mult Scler. 2015 May 26. pii: 1352458515581437.
    PubMed     Text format     Abstract available


  324. RAMANATHAN S, Sato S, Matsushita T, Masaki K, et al
    Antibodies to myelin oligodendrocyte glycoprotein are uncommon in Japanese opticospinal multiple sclerosis.
    Mult Scler. 2015 May 26. pii: 1352458515586089.
    PubMed     Text format    


  325. BJORNEVIK K, Riise T, Cortese M, Holmoy T, et al
    Level of education and multiple sclerosis risk after adjustment for known risk factors: The EnvIMS study.
    Mult Scler. 2015 May 26. pii: 1352458515579444.
    PubMed     Text format     Abstract available


  326. MACMILLAN EL, Tam R, Zhao Y, Vavasour IM, et al
    Progressive multiple sclerosis exhibits decreasing glutamate and glutamine over two years.
    Mult Scler. 2015 May 26. pii: 1352458515586086.
    PubMed     Text format     Abstract available


  327. DEASON K, Miller-Little WA, Stuve O
    Natalizumab and monocytes in multiple sclerosis: The dim haze of mystery and the enchantment of pursuit.
    Mult Scler. 2015 May 26. pii: 1352458515574150.
    PubMed     Text format    


  328. VAN DER WALT A, Buzzard K, Sung S, Spelman T, et al
    The occurrence of dystonia in upper-limb multiple sclerosis tremor.
    Mult Scler. 2015 May 26. pii: 1352458515577690.
    PubMed     Text format     Abstract available


  329. MATTIOLI F, Bellomi F, Stampatori C, Capra R, et al
    Neuroenhancement through cognitive training and anodal tDCS in multiple sclerosis.
    Mult Scler. 2015 May 26. pii: 1352458515587597.
    PubMed     Text format     Abstract available


  330. SCOLDING N
    The best clinical paper on multiple sclerosis in 2014.
    Mult Scler. 2015 May 7. pii: 1352458515584416.
    PubMed     Text format    


  331. HILVEN K, Patsopoulos NA, Dubois B, Goris A, et al
    Burden of risk variants correlates with phenotype of multiple sclerosis.
    Mult Scler. 2015 May 6. pii: 1352458514568174.
    PubMed     Text format     Abstract available


  332. HUTCHINSON M
    The best clinical paper on multiple sclerosis in 2014: Herodotus and Chataway - Commentary.
    Mult Scler. 2015 May 6. pii: 1352458515585135.
    PubMed     Text format    


  333. LULU S, Graves J, Waubant E
    Menarche increases relapse risk in pediatric multiple sclerosis.
    Mult Scler. 2015 May 6. pii: 1352458515581873.
    PubMed     Text format     Abstract available


  334. CORTESE M, Riise T, Bjornevik K, Holmoy T, et al
    Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: The EnvIMS study.
    Mult Scler. 2015 May 6. pii: 1352458515578770.
    PubMed     Text format     Abstract available


  335. MARTINS DA SILVA A, Cavaco S, Moreira I, Bettencourt A, et al
    Cognitive reserve in multiple sclerosis: Protective effects of education.
    Mult Scler. 2015 May 6. pii: 1352458515581874.
    PubMed     Text format     Abstract available


  336. MANOGARAN P, Vavasour I, Borich M, Kolind SH, et al
    Corticospinal tract integrity measured using transcranial magnetic stimulation and magnetic resonance imaging in neuromyelitis optica and multiple sclerosis.
    Mult Scler. 2015 May 6. pii: 1352458515579441.
    PubMed     Text format     Abstract available


  337. HAINES JD, Vidaurre OG, Zhang F, Riffo-Campos AL, et al
    Multiple sclerosis patient-derived CSF induces transcriptional changes in proliferating oligodendrocyte progenitors.
    Mult Scler. 2015 May 6. pii: 1352458515573094.
    PubMed     Text format     Abstract available


  338. LONGBRAKE EE, Cross AH
    Dimethyl fumarate associated lymphopenia in clinical practice.
    Mult Scler. 2015;21:796-7.
    PubMed     Text format    


  339. SASTRE-GARRIGA J, Tur C, Pareto D, Vidal-Jordana A, et al
    Brain atrophy in natalizumab-treated patients: A 3-year follow-up.
    Mult Scler. 2015;21:749-56.
    PubMed     Text format     Abstract available


  340. VIDAL-JORDANA A, Tintore M, Tur C, Perez-Miralles F, et al
    Significant clinical worsening after natalizumab withdrawal: Predictive factors.
    Mult Scler. 2015;21:780-5.
    PubMed     Text format     Abstract available


  341. COMI G, Gold R, Dahlke F, Sinha A, et al
    Relapses in patients treated with fingolimod after previous exposure to natalizumab.
    Mult Scler. 2015;21:786-90.
    PubMed     Text format     Abstract available


    April 2015
  342. HADJIXENOFONTOS A, Gourraud PA, Bakthavachalam V, Foco L, et al
    Enrichment for Northern European-derived multiple sclerosis risk alleles in Sardinia.
    Mult Scler. 2015 Apr 28. pii: 1352458515581872.
    PubMed     Text format     Abstract available


  343. CHEN DQ, DeSouza DD, Hayes DJ, Davis KD, et al
    Diffusivity signatures characterize trigeminal neuralgia associated with multiple sclerosis.
    Mult Scler. 2015 Apr 28. pii: 1352458515579440.
    PubMed     Text format     Abstract available


  344. GANDHI R
    miRNA in multiple sclerosis: search for novel biomarkers.
    Mult Scler. 2015 Apr 28. pii: 1352458515578771.
    PubMed     Text format     Abstract available


  345. PANDIT L, Malli C, Singhal B, Wason J, et al
    HLA associations in South Asian multiple sclerosis.
    Mult Scler. 2015 Apr 28. pii: 1352458515581439.
    PubMed     Text format     Abstract available


  346. MUSELLA A, Mandolesi G, Mori F, Gentile A, et al
    Linking synaptopathy and gray matter damage in multiple sclerosis.
    Mult Scler. 2015 Apr 28. pii: 1352458515581875.
    PubMed     Text format    


  347. JOENSEN P
    Reply to Article: High inbreeding in the Faroe Islands does not appear to constitute a risk factor for multiple sclerosis.
    Mult Scler. 2015 Apr 28. pii: 1352458515581440.
    PubMed     Text format    


  348. DEPPE M, Tabelow K, Kramer J, Tenberge JG, et al
    Evidence for early, non-lesional cerebellar damage in patients with multiple sclerosis: DTI measures correlate with disability, atrophy, and disease duration.
    Mult Scler. 2015 Apr 28. pii: 1352458515579439.
    PubMed     Text format     Abstract available


  349. NICHOLAS R, Magliozzi R, Campbell G, Mahad D, et al
    Temporal lobe cortical pathology and inhibitory GABA interneuron cell loss are associated with seizures in multiple sclerosis.
    Mult Scler. 2015 Apr 28. pii: 1352458515579445.
    PubMed     Text format     Abstract available


  350. SIMPSON R, Mair F, Mercer S
    Mindfulness-based interventions for people with multiple sclerosis.
    Mult Scler. 2015 Apr 28. pii: 1352458515579702.
    PubMed     Text format    


  351. MODICA CM, Bergsland N, Dwyer MG, Ramasamy DP, et al
    Cognitive reserve moderates the impact of subcortical gray matter atrophy on neuropsychological status in multiple sclerosis.
    Mult Scler. 2015 Apr 28. pii: 1352458515579443.
    PubMed     Text format     Abstract available


  352. FRISELL T, Forsberg L, Nordin N, Kiesel C, et al
    Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.
    Mult Scler. 2015 Apr 28. pii: 1352458515579216.
    PubMed     Text format     Abstract available


  353. HOANG P, Schoene D, Gandevia S, Smith S, et al
    Effects of a home-based step training programme on balance, stepping, cognition and functional performance in people with multiple sclerosis - a randomized controlled trial.
    Mult Scler. 2015 Apr 28. pii: 1352458515579442.
    PubMed     Text format     Abstract available


  354. NUNES JC, Radbruch H, Walz R, Lin K, et al
    The most fulminant course of the Marburg variant of multiple sclerosis-autopsy findings.
    Mult Scler. 2015;21:485-7.
    PubMed     Text format     Abstract available


  355. SINDIC C, Edan G
    Richard E Gonsette (1929-2014).
    Mult Scler. 2015;21:540.
    PubMed     Text format    


  356. PEAUREAUX D, Pignolet B, Biotti D, Bucciarelli F, et al
    Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
    Mult Scler. 2015;21:671-2.
    PubMed     Text format    


  357. PESCHL P, Reindl M, Schanda K, Sospedra M, et al
    Antibody responses following induction of antigen-specific tolerance with antigen-coupled cells.
    Mult Scler. 2015;21:651-5.
    PubMed     Text format     Abstract available


  358. ELLIS R, Brown S, Boggild M
    Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?
    Mult Scler. 2015;21:642-5.
    PubMed     Text format     Abstract available


  359. HANKEN K, Eling P, Hildebrandt H
    Is there a cognitive signature for MS-related fatigue?
    Mult Scler. 2015;21:376-81.
    PubMed     Text format     Abstract available


    March 2015
  360. OUTTERYCK O, Majed B, Defoort-Dhellemmes S, Vermersch P, et al
    A comparative optical coherence tomography study in neuromyelitis optica spectrum disorder and multiple sclerosis.
    Mult Scler. 2015 Mar 31. pii: 1352458515578888.
    PubMed     Text format     Abstract available


  361. SALZER J
    'The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level - YES'.
    Mult Scler. 2015 Mar 31. pii: 1352458515578773.
    PubMed     Text format    


  362. KOHLMANN R, Salmen A, Chan A, Knabbe C, et al
    Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis.
    Mult Scler. 2015 Mar 31. pii: 1352458515576984.
    PubMed     Text format     Abstract available


  363. PUTHENPARAMPIL M, Poggiali D, Causin F, Rolma G, et al
    Cortical relapses in multiple sclerosis.
    Mult Scler. 2015 Mar 19. pii: 1352458514564483.
    PubMed     Text format     Abstract available


  364. RITO Y, Flores J, Fernandez Aguilar A, Escalante Membrillo C, et al
    Vitamin D in multiple sclerosis patients: Not the same risk for everybody.
    Mult Scler. 2015 Mar 12. pii: 1352458515576986.
    PubMed     Text format    


  365. ROBERG BL, Bruce JM
    Reconsidering outdoor temperature and cognition in multiple sclerosis.
    Mult Scler. 2015 Mar 3. pii: 1352458515575172.
    PubMed     Text format     Abstract available


  366. MARTINEZ MA, Olsson B, Bau L, Matas E, et al
    Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.
    Mult Scler. 2015 Mar 2. pii: 1352458514549397.
    PubMed     Text format     Abstract available


  367. LUESSI F, Kraus S, Trinschek B, Lerch S, et al
    FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis.
    Mult Scler. 2015 Mar 2. pii: 1352458515574895.
    PubMed     Text format     Abstract available


    February 2015
  368. KOOIJ G, de Vries HE
    The best basic science paper in multiple sclerosis in 2014: Important role for the choroid plexus in the central nervous system entry of leukocytes.
    Mult Scler. 2015 Feb 25. pii: 1352458515573095.
    PubMed     Text format    


  369. GICH J, Freixanet J, Garcia R, Vilanova JC, et al
    A randomized, controlled, single-blind, 6-month pilot study to evaluate the efficacy of MS-Line!: a cognitive rehabilitation programme for patients with multiple sclerosis.
    Mult Scler. 2015 Feb 25. pii: 1352458515572405.
    PubMed     Text format     Abstract available


  370. SOLOMON AJ, Klein EP, Corboy JR, Bernat JL, et al
    Patient perspectives on physician conflict of interest in industry-sponsored clinical trials for multiple sclerosis therapeutics.
    Mult Scler. 2015 Feb 25. pii: 1352458515569101.
    PubMed     Text format     Abstract available


  371. PROSPERINI L, Annovazzi P, Capobianco M, Capra R, et al
    Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.
    Mult Scler. 2015 Feb 19. pii: 1352458515570768.
    PubMed     Text format     Abstract available


  372. VOLDSGAARD A, Bager P, Garde E, Akeson P, et al
    Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect.
    Mult Scler. 2015 Feb 19. pii: 1352458514568173.
    PubMed     Text format     Abstract available


  373. MODVIG S, Degn M, Roed H, Sorensen T, et al
    Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis.
    Mult Scler. 2015 Feb 19. pii: 1352458515574148.
    PubMed     Text format     Abstract available


  374. HINSINGER G, Galeotti N, Nabholz N, Urbach S, et al
    Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis.
    Mult Scler. 2015 Feb 19. pii: 1352458514561906.
    PubMed     Text format     Abstract available


  375. HUTCHINSON M
    The best basic science paper in multiple sclerosis in 2014: Citicoline, remyelination and neuroprotection: Commentary.
    Mult Scler. 2015 Feb 19. pii: 1352458515573096.
    PubMed     Text format    


  376. CULPEPPER WJ 2ND
    The incidence and prevalence of comorbidity in multiple sclerosis.
    Mult Scler. 2015 Feb 19. pii: 1352458515574151.
    PubMed     Text format    


  377. HEDSTROM A, Akerstedt T, Olsson T, Alfredsson L, et al
    Shift work influences multiple sclerosis risk.
    Mult Scler. 2015 Feb 19. pii: 1352458514563592.
    PubMed     Text format     Abstract available


  378. WIBERG M, Friberg E, Stenbeck M, Alexanderson K, et al
    Sources and level of income among individuals with multiple sclerosis compared to the general population: A nationwide population-based study.
    Mult Scler. 2015 Feb 19. pii: 1352458515570767.
    PubMed     Text format     Abstract available


  379. HULST HE, Schoonheim MM, Van Geest Q, Uitdehaag BM, et al
    Memory impairment in multiple sclerosis: Relevance of hippocampal activation and hippocampal connectivity.
    Mult Scler. 2015 Feb 13. pii: 1352458514567727.
    PubMed     Text format     Abstract available


  380. KUHLE J, Disanto G, Dobson R, Adiutori R, et al
    Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.
    Mult Scler. 2015 Feb 13. pii: 1352458514568827.
    PubMed     Text format     Abstract available


  381. LANZILLO R, Moccia M, Carotenuto A, Vacchiano V, et al
    Vitamin K cream reduces reactions at the injection site in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon beta - VIKING study.
    Mult Scler. 2015 Feb 6. pii: 1352458514562989.
    PubMed     Text format    


  382. REICH DS, White R, Cortese IC, Vuolo L, et al
    Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging.
    Mult Scler. 2015 Feb 6. pii: 1352458515569098.
    PubMed     Text format     Abstract available


  383. TRENTINI A, Manfrinato MC, Castellazzi M, Tamborino C, et al
    TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis.
    Mult Scler. 2015 Feb 6. pii: 1352458514560925.
    PubMed     Text format     Abstract available


  384. MULS NG, Dang HA, Sindic CJ, van Pesch V, et al
    Regulation of Treg-associated CD39 in multiple sclerosis and effects of corticotherapy during relapse.
    Mult Scler. 2015 Feb 6. pii: 1352458514567215.
    PubMed     Text format     Abstract available


  385. BERTONI R, Lamers I, Chen CC, Feys P, et al
    Unilateral and bilateral upper limb dysfunction at body functions, activity and participation levels in people with multiple sclerosis.
    Mult Scler. 2015 Feb 6. pii: 1352458514567553.
    PubMed     Text format     Abstract available


  386. VENNEGOOR A, van Rossum JA, Polman CH, Wattjes MP, et al
    Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Mult Scler. 2015 Feb 6. pii: 1352458514567728.
    PubMed     Text format     Abstract available


  387. BENNETT J, de Seze J, Lana-Peixoto M, Palace J, et al
    Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography.
    Mult Scler. 2015 Feb 6. pii: 1352458514567216.
    PubMed     Text format     Abstract available


    January 2015
  388. STEVENSON V, Gras A, Bardos J, Broughton J, et al
    The high cost of spasticity in multiple sclerosis to individuals and society.
    Mult Scler. 2015 Jan 26. pii: 1352458514566416.
    PubMed     Text format     Abstract available


  389. OLSSON A, Oturai D, Sorensen P, Oturai P, et al
    Short-term, high-dose glucocorticoid treatment does not contribute to reduced bone mineral density in patients with multiple sclerosis.
    Mult Scler. 2015 Jan 26. pii: 1352458514566417.
    PubMed     Text format     Abstract available


  390. LOPEZ DE LAPUENTE A, Pinto-Medel MJ, Astobiza I, Alloza I, et al
    Cell-specific effects in different immune subsets associated with SOCS1 genotypes in multiple sclerosis.
    Mult Scler. 2015 Jan 26. pii: 1352458514566418.
    PubMed     Text format     Abstract available


  391. GIOVANNONI G
    Any evident MRI T2-lesion activity should guide change of therapy in multiple sclerosis - Yes.
    Mult Scler. 2015 Jan 26. pii: 1352458514566261.
    PubMed     Text format    


  392. DE STEFANO N, Arnold DL
    Towards a better understanding of pseudoatrophy in the brain of multiple sclerosis patients.
    Mult Scler. 2015 Jan 26. pii: 1352458514564494.
    PubMed     Text format    


  393. HUTCHINSON M
    Any evident MRI T2 lesion activity should guide change of therapy in multiple sclerosis - Commentary.
    Mult Scler. 2015 Jan 26. pii: 1352458514565960.
    PubMed     Text format    


  394. KAMM CP, Mattle HP, Muri RM, Heldner MR, et al
    Home-based training to improve manual dexterity in patients with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2015 Jan 26. pii: 1352458514565959.
    PubMed     Text format     Abstract available


  395. KREMER D, Kury P, Dutta R
    Promoting remyelination in multiple sclerosis: Current drugs and future prospects.
    Mult Scler. 2015 Jan 26. pii: 1352458514566419.
    PubMed     Text format     Abstract available


  396. MARRIE RA, Cohen J, Stuve O, Trojano M, et al
    A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview.
    Mult Scler. 2015 Jan 26. pii: 1352458514564491.
    PubMed     Text format     Abstract available


  397. GANDOLFI M, Munari D, Geroin C, Gajofatto A, et al
    Sensory integration balance training in patients with multiple sclerosis: A randomized, controlled trial.
    Mult Scler. 2015 Jan 12. pii: 1352458514562438.
    PubMed     Text format     Abstract available


  398. HARRISON DM, Oh J, Roy S, Wood ET, et al
    Thalamic lesions in multiple sclerosis by 7T MRI: Clinical implications and relationship to cortical pathology.
    Mult Scler. 2015 Jan 12. pii: 1352458514558134.
    PubMed     Text format     Abstract available


  399. SOLARO C, Ponzio M, Moran E, Tanganelli P, et al
    The changing face of multiple sclerosis: Prevalence and incidence in an aging population.
    Mult Scler. 2015 Jan 12. pii: 1352458514561904.
    PubMed     Text format     Abstract available


  400. HEMMER B
    Antibodies to the inward rectifying potassium channel 4.1 in multiple sclerosis: different methodologies--conflicting results?
    Mult Scler. 2015 Jan 12. pii: 1352458514564493.
    PubMed     Text format    


  401. FAGNANI C, Neale MC, Nistico L, Stazi MA, et al
    Twin studies in multiple sclerosis: A meta-estimation of heritability and environmentality.
    Mult Scler. 2015 Jan 12. pii: 1352458514564492.
    PubMed     Text format     Abstract available


  402. HAAS J, Schwarz A, Korporal-Kunke M, Jarius S, et al
    Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis.
    Mult Scler. 2015 Jan 12. pii: 1352458514564589.
    PubMed     Text format     Abstract available


  403. MARRIE RA, Reingold S, Cohen J, Stuve O, et al
    The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review.
    Mult Scler. 2015 Jan 12. pii: 1352458514564487.
    PubMed     Text format     Abstract available


  404. NIINO M, Sato S, Fukazawa T, Yoshimura S, et al
    Latitude and HLA-DRB1 alleles independently affect the emergence of cerebrospinal fluid IgG abnormality in multiple sclerosis.
    Mult Scler. 2015 Jan 12. pii: 1352458514560924.
    PubMed     Text format     Abstract available


  405. RAZAZ N, Tremlett H, Boyce WT, Guhn M, et al
    Impact of parental multiple sclerosis on early childhood development: A retrospective cohort study.
    Mult Scler. 2015 Jan 12. pii: 1352458514559298.
    PubMed     Text format     Abstract available


  406. SETTLE JR, Robinson SA, Kane R, Maloni HW, et al
    Remote cognitive assessments for patients with multiple sclerosis: a feasibility study.
    Mult Scler. 2015 Jan 12. pii: 1352458514559296.
    PubMed     Text format     Abstract available


  407. GIACALONE G, Clarelli F, Osiceanu A, Guaschino C, et al
    Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis.
    Mult Scler. 2015 Jan 12. pii: 1352458514564590.
    PubMed     Text format     Abstract available


  408. CURRO' D, Vuolo L, Gualandi F, Bacigalupo A, et al
    Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study.
    Mult Scler. 2015 Jan 12. pii: 1352458514564484.
    PubMed     Text format     Abstract available


  409. STRIJBOS E, Coenradie S, Touw D, Aerden L, et al
    High-dose methylprednisolone for multiple sclerosis during lactation: Concentrations in breast milk.
    Mult Scler. 2015 Jan 12. pii: 1352458514565414.
    PubMed     Text format    


  410. BARRETT L, Cano S, Zajicek J, Hobart J, et al
    Lending a hand: Can DASH items help ABILHAND improve manual ability measurement in multiple sclerosis?
    Mult Scler. 2015 Jan 12. pii: 1352458514549396.
    PubMed     Text format     Abstract available


  411. MCCOMBE PA, Stenager E
    Female infertility and multiple sclerosis: Is this an issue?
    Mult Scler. 2015 Jan 12. pii: 1352458514549406.
    PubMed     Text format    


  412. RIO J
    Any evident MRI T2 lesion activity should guide change of therapy in multiple sclerosis: No.
    Mult Scler. 2015 Jan 12. pii: 1352458514565415.
    PubMed     Text format    


  413. POPESCU V, Klaver R, Voorn P, Galis-de Graaf Y, et al
    What drives MRI-measured cortical atrophy in multiple sclerosis?
    Mult Scler. 2015 Jan 12. pii: 1352458514562440.
    PubMed     Text format     Abstract available


  414. GOODMAN AD, Bethoux F, Brown TR, Schapiro RT, et al
    Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
    Mult Scler. 2015 Jan 12. pii: 1352458514563591.
    PubMed     Text format     Abstract available


  415. HAUSER SL
    The Charcot Lecture | beating MS: a story of B cells, with twists and turns.
    Mult Scler. 2015;21:8-21.
    PubMed     Text format     Abstract available


  416. VAN SCHEPENDOM J, D'hooghe MB, Cleynhens K, D'hooge M, et al
    Reduced information processing speed as primum movens for cognitive decline in MS.
    Mult Scler. 2015;21:83-91.
    PubMed     Text format     Abstract available


  417. NILSAGARD Y, Gunn H, Freeman J, Hoang P, et al
    Falls in people with MS--an individual data meta-analysis from studies from Australia, Sweden, United Kingdom and the United States.
    Mult Scler. 2015;21:92-100.
    PubMed     Text format     Abstract available


    December 2014
  418. MARRIE RA, Reider N, Stuve O, Trojano M, et al
    The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review.
    Mult Scler. 2014 Dec 23. pii: 1352458514564488.
    PubMed     Text format     Abstract available


  419. HUTCHINSON M
    We can compare the relative efficacy multiple sclerosis medications by examining the results of independent clinical trials: Commentary.
    Mult Scler. 2014 Dec 22. pii: 1352458514564591.
    PubMed     Text format    


  420. MARRIE RA, Reider N, Cohen J, Stuve O, et al
    A systematic review of the incidence and prevalence of cancer in multiple sclerosis.
    Mult Scler. 2014 Dec 22. pii: 1352458514564489.
    PubMed     Text format     Abstract available


  421. MARRIE RA, Reider N, Cohen J, Trojano M, et al
    A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis.
    Mult Scler. 2014 Dec 22. pii: 1352458514564486.
    PubMed     Text format     Abstract available


  422. MARRIE RA, Reider N, Cohen J, Stuve O, et al
    A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis.
    Mult Scler. 2014 Dec 22. pii: 1352458514564485.
    PubMed     Text format     Abstract available


  423. MARRIE RA, Reider N, Cohen J, Stuve O, et al
    A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis.
    Mult Scler. 2014 Dec 22. pii: 1352458514564490.
    PubMed     Text format     Abstract available


  424. FERNANDEZ-JIMENEZ E, Arnett PA
    Impact of neurological impairment, depression, cognitive function and coping on quality of life of people with multiple sclerosis: A relative importance analysis.
    Mult Scler. 2014 Dec 22. pii: 1352458514562439.
    PubMed     Text format     Abstract available


  425. FEINSTEIN A
    Is there a cognitive signature for multiple sclerosis-related fatigue?
    Mult Scler. 2014 Dec 22. pii: 1352458514563099.
    PubMed     Text format    


  426. TAYLOR M, Griffin M
    The use of gaming technology for rehabilitation in people with multiple sclerosis.
    Mult Scler. 2014 Dec 22. pii: 1352458514563593.
    PubMed     Text format     Abstract available


  427. LAURSEN JH, Sondergaard HB, Albrechtsen A, Frikke-Schmidt R, et al
    Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis.
    Mult Scler. 2014 Dec 22. pii: 1352458514563590.
    PubMed     Text format     Abstract available


  428. NIGRO S, Passamonti L, Riccelli R, Toschi N, et al
    Structural 'connectomic' alterations in the limbic system of multiple sclerosis patients with major depression.
    Mult Scler. 2014 Dec 22. pii: 1352458514558474.
    PubMed     Text format     Abstract available


  429. MASERA S, Cavalla P, Prosperini L, Mattioda A, et al
    Parity is associated with a longer time to reach irreversible disability milestones in women with multiple sclerosis.
    Mult Scler. 2014 Dec 22. pii: 1352458514561907.
    PubMed     Text format     Abstract available


  430. SOROSINA M, Esposito F, Guaschino C, Clarelli F, et al
    Inverse correlation of genetic risk score with age at onset in bout-onset and progressive-onset multiple sclerosis.
    Mult Scler. 2014 Dec 22. pii: 1352458514561910.
    PubMed     Text format     Abstract available


  431. AHN JJ, O'Mahony J, Moshkova M, Hanwell HE, et al
    Puberty in females enhances the risk of an outcome of multiple sclerosis in children and the development of central nervous system autoimmunity in mice.
    Mult Scler. 2014 Dec 22. pii: 1352458514551453.
    PubMed     Text format     Abstract available


  432. CHECA A, Khademi M, Sar DG, Haeggstrom JZ, et al
    Hexosylceramides as intrathecal markers of worsening disability in multiple sclerosis.
    Mult Scler. 2014 Dec 5. pii: 1352458514561908.
    PubMed     Text format     Abstract available


  433. GRANBERG T, Martola J, Bergendal G, Shams S, et al
    Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: Results of a 17-year longitudinal study.
    Mult Scler. 2014 Dec 5. pii: 1352458514560928.
    PubMed     Text format     Abstract available


  434. GICH J, Freixenet J, Garcia R, Vilanova JC, et al
    A new cognitive rehabilitation programme for patients with multiple sclerosis: the 'MS-line! Project'
    Mult Scler. 2014 Dec 5. pii: 1352458514561905.
    PubMed     Text format     Abstract available


  435. WEIER K, Eshaghi A, Magon S, Andelova M, et al
    The role of cerebellar abnormalities in neuromyelitis optica - a comparison with multiple sclerosis and healthy controls.
    Mult Scler. 2014 Dec 5. pii: 1352458514554051.
    PubMed     Text format     Abstract available


  436. HAGHIKIA A, Faissner S, Pappas D, Pula B, et al
    Interferon-beta affects mitochondrial activity in CD4+ lymphocytes: Implications for mechanism of action in multiple sclerosis.
    Mult Scler. 2014 Dec 5. pii: 1352458514561909.
    PubMed     Text format     Abstract available


  437. AUNG LL, Balashov KE
    Decreased Dicer expression is linked to increased expression of co-stimulatory molecule CD80 on B cells in multiple sclerosis.
    Mult Scler. 2014 Dec 5. pii: 1352458514560923.
    PubMed     Text format     Abstract available


  438. GHASSEMI R, Brown R, Banwell B, Narayanan S, et al
    Quantitative Measurement of tissue damage and recovery within new T2w lesions in pediatric- and adult-onset multiple sclerosis.
    Mult Scler. 2014 Dec 5. pii: 1352458514551594.
    PubMed     Text format     Abstract available


  439. KALINCIK T, Jokubaitis V, Izquierdo G, Duquette P, et al
    Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.
    Mult Scler. 2014 Dec 5. pii: 1352458514559865.
    PubMed     Text format     Abstract available


  440. MARRIE RA
    Psychiatric comorbidity in multiple sclerosis: It's not the genes.
    Mult Scler. 2014;20:1803-5.
    PubMed     Text format    


    November 2014
  441. KIESEIER BC, Arnold DL, Balcer LJ, Boyko AA, et al
    Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE.
    Mult Scler. 2014 Nov 28. pii: 1352458514557986.
    PubMed     Text format     Abstract available


  442. LABIANO-FONTCUBERTA A, Mitchell AJ, Moreno-Garcia S, Puertas-Martin V, et al
    Impact of anger on the health-related quality of life of multiple sclerosis patients.
    Mult Scler. 2014 Nov 28. pii: 1352458514549399.
    PubMed     Text format     Abstract available


  443. ARTEMIADIS A, Nikolaou G, Kolokythopoulos D, Tegos N, et al
    Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient.
    Mult Scler. 2014 Nov 28. pii: 1352458514555788.
    PubMed     Text format    


  444. CALABRESE M, Gajofatto A, Gobbin F, Turri G, et al
    Late-onset multiple sclerosis presenting with cognitive dysfunction and severe cortical/infratentorial atrophy.
    Mult Scler. 2014 Nov 28. pii: 1352458514542363.
    PubMed     Text format     Abstract available


  445. WIDDIFIELD J, Ivers NM, Young J, Green D, et al
    Development and validation of an administrative data algorithm to estimate the disease burden and epidemiology of multiple sclerosis in Ontario, Canada.
    Mult Scler. 2014 Nov 12. pii: 1352458514556303.
    PubMed     Text format     Abstract available


  446. BRICHETTO G, Piccardo E, Pedulla L, Battaglia MA, et al
    Tailored balance exercises on people with multiple sclerosis: A pilot randomized, controlled study.
    Mult Scler. 2014 Nov 12. pii: 1352458514557985.
    PubMed     Text format     Abstract available


  447. HUTCHINSON M
    The best basic science paper in multiple sclerosis in 2013: Disease specific molecular events in cortical multiple sclerosis lesions.
    Mult Scler. 2014 Nov 12. pii: 1352458514558342.
    PubMed     Text format    


  448. COSSU D, Mameli G, Galleri G, Cocco E, et al
    Human interferon regulatory factor 5 homologous epitopes of Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis induce a specific humoral and cellular immune response in multiple sclerosis patients.
    Mult Scler. 2014 Nov 12. pii: 1352458514557304.
    PubMed     Text format     Abstract available


  449. CICCARELLI O, Chataway J
    We can compare the relative efficacy of multiple sclerosis medications by examining the results of independent clinical trials: No.
    Mult Scler. 2014 Nov 12. pii: 1352458514559866.
    PubMed     Text format    


  450. WANG C, Paling D, Chen L, Hatton SN, et al
    Axonal conduction in multiple sclerosis: A combined magnetic resonance imaging and electrophysiological study of the medial longitudinal fasciculus.
    Mult Scler. 2014 Nov 12. pii: 1352458514556301.
    PubMed     Text format     Abstract available


  451. ROCCA MA, De Meo E, Amato MP, Copetti M, et al
    Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions.
    Mult Scler. 2014 Nov 12. pii: 1352458514557303.
    PubMed     Text format     Abstract available


  452. BINZER S, Imrell K, Binzer M, Kyvik KO, et al
    High inbreeding in the Faroe Islands does not appear to constitute a risk factor for multiple sclerosis.
    Mult Scler. 2014 Nov 12. pii: 1352458514557305.
    PubMed     Text format     Abstract available


  453. DELGADO-GARCIA M, Matesanz F, Alcina A, Fedetz M, et al
    A new risk variant for multiple sclerosis at the immunoglobulin heavy chain locus associates with intrathecal IgG, IgM index and oligoclonal bands.
    Mult Scler. 2014 Nov 12. pii: 1352458514556302.
    PubMed     Text format     Abstract available


  454. KAVAK KS, Teter BE, Hagemeier J, Zakalik K, et al
    Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset.
    Mult Scler. 2014 Nov 12. pii: 1352458514555787.
    PubMed     Text format     Abstract available


  455. DAHDALEH D, Sharrack B
    We can compare the relative efficacy of multiple sclerosis medications by examining the results of independent clinical trials: Yes.
    Mult Scler. 2014 Nov 12. pii: 1352458514558678.
    PubMed     Text format    


  456. DERFUSS T, Curtin F, Guebelin C, Bridel C, et al
    A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.
    Mult Scler. 2014 Nov 12. pii: 1352458514554052.
    PubMed     Text format     Abstract available


  457. BRILL L, Goldberg L, Karni A, Petrou P, et al
    Increased anti-KIR4.1 antibodies in multiple sclerosis: Could it be a marker of disease relapse?
    Mult Scler. 2014 Nov 12. pii: 1352458514551779.
    PubMed     Text format     Abstract available


  458. CHIARINI M, Sottini A, Bertoli D, Serana F, et al
    Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients.
    Mult Scler. 2014 Nov 12. pii: 1352458514551456.
    PubMed     Text format     Abstract available


  459. FINKE C, Schlichting J, Papazoglou S, Scheel M, et al
    Altered basal ganglia functional connectivity in multiple sclerosis patients with fatigue.
    Mult Scler. 2014 Nov 12. pii: 1352458514555784.
    PubMed     Text format     Abstract available


  460. BARANZINI SE, Madireddy LR, Cromer A, D'Antonio M, et al
    Prognostic biomarkers of IFNb therapy in multiple sclerosis patients.
    Mult Scler. 2014 Nov 12. pii: 1352458514555786.
    PubMed     Text format     Abstract available


  461. BESTER M, Jensen J, Babb J, Tabesh A, et al
    Non-Gaussian diffusion MRI of gray matter is associated with cognitive impairment in multiple sclerosis.
    Mult Scler. 2014 Nov 12. pii: 1352458514556295.
    PubMed     Text format     Abstract available


  462. SIMPSON S JR, Taylor BV
    The Scandinavian paradox revisited: Editorial comment on Berg-Hansen et al. 'High prevalence and no latitude gradient of multiple sclerosis in Norway'.
    Mult Scler. 2014;20:1675-7.
    PubMed     Text format    


    October 2014
  463. ALROUGHANI R
    High discontinuation rate of natalizumab in JC virus seropositive patients due to significant anxiety and safety feelings.
    Mult Scler. 2014;20:1667-8.
    PubMed     Text format    


    August 2014
  464. VAN ROSSUM JA, Vennegoor A, Killestein J
    The effect of prolonged natalizumab treatment on anxiety and safety in JC virus-seropositive MS patients; a follow-up study.
    Mult Scler. 2014 Aug 11. pii: 1352458514543341.
    PubMed     Text format    


    July 2014
  465. VENNEGOOR A, Rispens T, Van Oosten B, Wattjes M, et al
    Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
    Mult Scler. 2014 Jul 30. pii: 1352458514541507.
    PubMed     Text format     Abstract available


    May 2014
  466. MATELL H, Lycke J, Svenningsson A, Holmen C, et al
    Age-dependent effects on the treatment response of natalizumab in MS patients.
    Mult Scler. 2014 May 27. pii: 1352458514536085.
    PubMed     Text format     Abstract available


  467. VIDAL-JORDANA A
    Comment on 'isolated bilateral horizontal gaze palsy as first manifestation of multiple sclerosis' by Stefan Kipfer and David W Crook.
    Mult Scler. 2014;20:756.
    PubMed     Text format    


  468. RAMIEN C, Pachnio A, Sisay S, Begum J, et al
    Hypovitaminosis-D and EBV: no interdependence between two MS risk factors in a healthy young UK autumn cohort.
    Mult Scler. 2014;20:751-3.
    PubMed     Text format     Abstract available


  469. CARRUTHERS RL, Chitnis T, Healy BC
    Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
    Mult Scler. 2014;20:757-60.
    PubMed     Text format     Abstract available


  470. RAMO-TELLO C, Grau-Lopez L, Tintore M, Rovira A, et al
    A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.
    Mult Scler. 2014;20:717-25.
    PubMed     Text format     Abstract available


    April 2014
  471. MATTHEWS PM
    The virtues of adaptability.
    Mult Scler. 2014;20:394-6.
    PubMed     Text format    


  472. TUR C, Montalban X
    Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al.
    Mult Scler. 2014;20:510-1.
    PubMed     Text format    


  473. ELSONE L, Panicker J, Mutch K, Boggild M, et al
    Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients.
    Mult Scler. 2014;20:501-4.
    PubMed     Text format     Abstract available


  474. FRANCIS G, Kappos L, O'Connor P, Collins W, et al
    Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy.
    Mult Scler. 2014;20:471-80.
    PubMed     Text format     Abstract available


  475. HEDSTROM AK, Ryner M, Fink K, Fogdell-Hahn A, et al
    Smoking and risk of treatment-induced neutralizing antibodies to interferon beta-1a.
    Mult Scler. 2014;20:445-50.
    PubMed     Text format     Abstract available


  476. HUH SY, Kim SH, Kim W, Lee SH, et al
    Evaluation of McDonald MRI criteria for dissemination in space in Korean patients with clinically isolated syndromes.
    Mult Scler. 2014;20:492-5.
    PubMed     Text format     Abstract available


  477. HEDSTROM AK, Hillert J, Olsson T, Alfredsson L, et al
    Reverse causality behind the association between reproductive history and MS.
    Mult Scler. 2014;20:406-11.
    PubMed     Text format     Abstract available


  478. ROVIRA A, Auger C
    Cortical lesion counts by double inversion recovery should be part of the MRI monitoring process for all MS patients: Commentary.
    Mult Scler. 2014;20:541-2.
    PubMed     Text format    


  479. CHARD D
    Cortical lesion counts by double inversion recovery should be part of the MRI monitoring process for all MS patients: No.
    Mult Scler. 2014;20:539-40.
    PubMed     Text format    


  480. CALABRESE M, De Stefano N
    Cortical lesion counts by double inversion recovery should be part of the MRI monitoring process for all MS patients: Yes.
    Mult Scler. 2014;20:537-8.
    PubMed     Text format    


  481. SATO DK, Misu T, Rocha CF, Callegaro D, et al
    Aquaporin-4 antibody-positive myelitis initially biopsied for suspected spinal cord tumors: diagnostic considerations.
    Mult Scler. 2014;20:621-6.
    PubMed     Text format     Abstract available


  482. RINGELSTEIN M, Kleiter I, Ayzenberg I, Borisow N, et al
    Visual evoked potentials in neuromyelitis optica and its spectrum disorders.
    Mult Scler. 2014;20:617-20.
    PubMed     Text format     Abstract available


  483. HUYS AC, Lalive PH, Sekoranja L
    Fingolimod in a patient with Wolff-Parkinson-White syndrome.
    Mult Scler. 2014;20:636-7.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: